The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design by Dimairo, M. et al.
This is a repository copy of The Adaptive designs CONSORT Extension (ACE) statement: 
a checklist with explanation and elaboration guideline for reporting randomised trials that 
use an adaptive design.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/162013/
Version: Published Version
Article:
Dimairo, M. orcid.org/0000-0002-9311-6920, Pallmann, P., Wason, J. et al. (16 more 
authors) (2020) The Adaptive designs CONSORT Extension (ACE) statement: a checklist 
with explanation and elaboration guideline for reporting randomised trials that use an 
adaptive design. BMJ, 369. m115. ISSN 1759-2151 
https://doi.org/10.1136/bmj.m115
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
ReseaRch Methods and RepoRting
the bmj | BMJ 2020;369:m115 | doi: 10.1136/bmj.m115 1
The Adaptive designs CONSORT Extension (ACE) statement: a 
checklist with explanation and elaboration guideline for reporting 
randomised trials that use an adaptive design
Munyaradzi Dimairo,1 Philip Pallmann,2 James Wason,3,4 Susan Todd,5 Thomas Jaki,6  
Steven A Julious,1 Adrian P Mander,2,3 Christopher J Weir,7 Franz Koenig,8 Marc K Walton,9  
Jon P Nicholl,1 Elizabeth Coates,1 Katie Biggs,1 Toshimitsu Hamasaki,10 Michael A Proschan,11 
John A Scott,12 Yuki Ando,13 Daniel Hind,1 Douglas G Altman,14 on behalf of the ACE Consensus 
Group
Adaptive designs (ADs) allow pre-
planned changes to an ongoing trial 
without compromising the validity of 
conclusions and it is essential to 
distinguish pre-planned from 
unplanned changes that may also 
occur. The reporting of ADs in 
randomised trials is inconsistent and 
needs improving. Incompletely 
reported AD randomised trials are 
di cult to reproduce and are hard to 
interpret and synthesise. This 
consequently hampers their ability to 
inform practice as well as future 
research and contributes to research 
waste. Better transparency and 
adequate reporting will enable the 
potential beneits of ADs to be realised.
This extension to the Consolidated Standards Of 
Reporting Trials (CONSORT) 2010 statement was 
developed to enhance the reporting of randomised 
AD clinical trials. We developed an Adaptive designs 
CONSORT Extension (ACE) guideline through a two-
stage Delphi process with input from multidisci- 
plinary key stakeholders in clinical trials research 
in the public and private sectors from 21 countries, 
followed by a consensus meeting. Members of the 
CONSORT Group were involved during the development 
process.
The paper presents the ACE checklists for AD 
randomised trial reports and abstracts, as well as an 
explanation with examples to aid the application of 
the guideline. The ACE checklist comprises seven 
new items, nine modiied items, six unchanged items 
for which additional explanatory text clariies further 
considerations for ADs, and 20 unchanged items not 
requiring further explanatory text. The ACE abstract 
checklist has one new item, one modiied item, one 
unchanged item with additional explanatory text for 
ADs, and 15 unchanged items not requiring further 
explanatory text.
The intention is to enhance transparency and 
improve reporting of AD randomised trials to improve 
the interpretability of their results and reproducibility 
of their methods, results and inference. We also hope 
indirectly to facilitate the much-needed knowledge 
transfer of innovative trial designs to maximise their 
potential beneits.
“To maximise the beneit to society, you need to not 
just do research but do it well” Douglas G Altman
Purpose of the paper
Incomplete and poor reporting of randomised clinical 
trials makes trial indings diicult to interpret due to 
study methods, results, and inference that are not 
reproducible. This severely undermines the value of 
scientiic research, obstructs robust evidence synthesis 
to inform practice and future research, and contributes 
to research waste.1 2 The Consolidated Standards Of 
Reporting Trials (CONSORT) statement is a consensus-
based reporting guidance framework that aims to 
promote and enhance transparent and adequate 
reporting of randomised trials.3 4 Speciic CONSORT 
extensions addressing the reporting needs for parti-
cular trial designs, hypotheses, and interventions 
have been developed.5 The use of reporting guidelines 
is associated with improved completeness in study 
reporting6-8; however, mechanisms to improve 
adherence to reporting guidelines are needed.9-12
We developed an Adaptive designs CONSORT 
Extension (ACE)13 to the CONSORT 2010 statement3 4 
to support reporting of randomised trials that use an 
adaptive design (AD)—referred to as AD randomised 
trials. In this paper, we deine an AD and summarise 
some types of ADs as well as their use and reporting. 
We then describe briely how the ACE guideline was 
developed, and present its scope and underlying 
principles. Finally, we present the ACE checklist with 
explanation and elaboration (E&E) to guide its use.
Adaptive designs: definition, current use, and reporting
The ACE Steering Committee13 agreed a deinition of an 
AD (box 1) consistent with the literature.14-18
Substantial uncertainties often exist when designing 
trials around aspects such as the target population, 
outcome variability, optimal treatments for testing, 
treatment duration, treatment intensity, outcomes 
to measure, and measures of treatment efect.19 Well 
designed and conducted AD trials allow researchers to 
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address research questions more eiciently by allowing 
key aspects or assumptions of ongoing trials to be 
evaluated or validly stopping treatment arms or entire 
trials on the basis of available evidence.15 18 20 21 As a 
result, patients may receive safe, efective treatments 
sooner than with ixed (non-adaptive) designs.19 22-25 
Despite their potential beneits, there are practical 
challenges and obstacles to the use of ADs.18 26-33
The literature on ADs is considerable, and there is 
speciic terminology associated with the ield. Box 2 
gives a glossary of key terminology used throughout 
this E&E document.
Table 1 summarises some types of ADs and cites 
examples of their use in randomised trials. The 
motivations for these trial adaptations are well 
discussed.15 18 21 22 25 34-36 Notably, classiication of ADs 
in the literature is inconsistent,13 22 while the scope 
and complexity of trial adaptations and underpinning 
statistical methods continues to broaden.18 20 37
Furthermore, there is growing literature citing AD 
methods29 82 107 and interest in their application by 
researchers and research funders.26 28 108 Regulators 
have published relection and guidance papers on 
ADs.14 108-111 Several studies, including regulatory 
reviews, have investigated the use of ADs in randomised 
trials.27 29 31 33 41 49 101 107 108 112-119 In summary, ADs are 
used in a relatively low proportion of trials, although 
their use is steadily increasing in both the public 
and private sectors,114-116 and they are frequently 
considered at the design stage.27
The use of ADs is likely to be underestimated due to 
poor reporting making it diicult to retrieve them in the 
literature.114 While the reporting of standard CONSORT 
requirements of AD randomised trials is generally 
comparable to that of traditional ixed design trials,49 
inadequate and inconsistent reporting of essential 
aspects relating to ADs is widely documented.26 27 
49 107 112 113 120-122 This may limit their credibility, the 
interpretability of results, and their ability to inform 
or change practice,14 26-28 30 31 108 109 112 119 120 whereas 
transparency and adequate reporting can help address 
these concerns.22 27 In summary, statistical and non-
statistical issues arise in ADs,22 36 101 108 123-127 which 
require special reporting considerations.13
Summary of how the ACE guideline was developed
We adhered to a registered protocol128 and the 
consensus-driven methodological framework for 
developing healthcare reporting guidelines recom-
mended by the CONSORT Group and the Enhancing 
the QUAlity and Transparency Of health Research 
(EQUATOR) Network.129 An open access paper detailing 
the rationale and the complete development process of 
the ACE checklist for main reports and abstracts has 
been published.13 That paper details how reporting 
items were identiied, the stakeholders who were 
involved, the decision-making process, consensus 
judgement and how reporting items were retained 
or dropped, and inalisation of the ACE checklist. In 
summary, this comprised a two-stage Delphi process 
involving cross-sector (public and private) and 
multidisciplinary key stakeholders in clinical trials 
research from 21 countries. Delphi survey response 
rates were 94/143 (66%), 114/156 (73%), and 79/143 
(55%) in round one, round two, and across both 
rounds, respectively. A consensus meeting attended 
by 27 cross-sector delegates from Europe, Asia, and 
the US followed this. Members of the CONSORT Group 
provided oversight throughout. The ACE Consensus 
Group and Steering Committee approved the inal 
checklist that included the abstract and contributed 
to this E&E document. Box 3 outlines the scope of 
principles guiding the application of this extension.
Structure of the ACE guideline
Authors should apply this guideline together with the 
CONSORT 2010 statement3 4 and any other relevant 
extensions depending on other design features of their 
AD randomised trial (such as extensions for multi-
arm,132 cluster randomised,133 crossover,134 and non-
inferiority and equivalence trials135). Box 4 summarises 
the changes made to develop this extension. Table 
2 shows which CONSORT 2010 items were adapted 
and how. We provide both CONSORT 2010 and ACE 
items with comments, explanation, and examples 
to illustrate how speciic aspects of diferent types 
of AD randomised trials should be reported. For the 
examples, we obtained some additional information 
from researchers or other trial documents (such 
as statistical analysis plans (SAPs) and protocols). 
Headings of examples indicate the type of AD and the 
speciic elements of an item that were better reported, 
so examples may include some incomplete reporting in 
relation to other elements.
The ACE checklist
Tables 2 and 3 are checklists for the main report and 
abstract, respectively. Only new and modiied items are 
discussed in this E&E document, as well as six items 
that retain the CONSORT 20103 4 wording but require 
clariication for certain ADs (box 4). Authors should 
download and complete appendix A to accompany a 
manuscript during journal submission.
Section 1. Title and abstract
Ŷ CONSORT 2010 item 1b: Structured summary of 
trial design, methods, results, and conclusions (for 
speciic guidance see CONSORT for abstracts136 137)
Ŷ ACE item 1b: Structured summary of trial design, 
methods, results, and conclusions (for speciic 
guidance see ACE for abstracts, table 3)
Explanation—A well structured abstract summary 
encompassing trial design, methods, results, and 
conclusions is essential regardless of the type of 
Box 1: Deinition of an adaptive design (AD)
A clinical trial design that offers pre-planned opportunities to use accumulating trial 
data to modify aspects of an ongoing trial while preserving the validity and integrity of 
that trial.
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design implemented.137 This allows readers to search 
for relevant studies of interest and to quickly judge 
if the reported trial is relevant to them for further 
reading. Furthermore, it helps readers to make 
instant judgements on key beneits and risks of study 
interventions. Table 3 presents minimum essential 
items authors should report in an AD randomised 
trial abstract. Authors should use this extension 
together with the CONSORT for journal and conference 
abstracts for additional details136 137 and other relevant 
extensions where appropriate.
Ŷ CONSORT abstract item (Trial design): Description 
of the trial design (for example, parallel, cluster, 
non-inferiority)
Ŷ ACE abstract item (Trial design): Description of 
the trial design (for example, parallel, cluster, non-
inferiority); include the word “adaptive” in the 
content or at least as a keyword
Explanation—AD randomised trials should be 
indexed properly to allow other researchers to easily 
retrieve them in literature searches. This is particularly 
important as trial design may inluence interpretation 
of trial indings and the evidence synthesis approach 
used during meta-analyses. The MEDLINE database 
provides “Adaptive clinical trial” as a Medical Subject 
Heading (MeSH) topic to improve indexing.139 Authors 
may also like to state the type of the AD, including 
details of adaptations as covered under the new item 
3b (table 3). See box 5 for exemplars.
Ŷ CONSORT/ACE abstract item (Outcome): Clearly 
deined primary outcome for this report
Explanation—In some AD randomised trials, the 
outcome used to inform adaptations (adaptation 
outcome) and the primary outcome of the study can 
difer (see item 6 of the main checklist for details). The 
necessity of reporting both of these outcomes and results 
in the abstract depends on the stage of reporting and 
whether the adaptation decisions made were critical to 
inluencing the interpretation of the inal results. For 
example, when a trial or at least a treatment group is 
stopped early, based on an adaptation outcome which 
is not the primary outcome, it becomes essential to 
adequately describe both outcomes in accordance with 
the CONSORT 2010 statement.3 4 Contrarily, only the 
description of the primary outcome in the abstract will 
be essential when non-terminal adaptation decisions 
are made (such as to change the sample size, update 
randomisation, or no dropping of treatments groups 
at interims) and when inal (not interim) results are 
being reported. Furthermore, the results item (table 3) 
should be reported consistent with the stated primary 
and adaptation outcome(s), where necessary. See box 
6 for exemplars.
Ŷ ACE abstract item (adaptation decisions made): 
Specify what trial adaptation decisions were made 
in light of the pre-planned decision-making criteria 
and observed accrued data
Explanation—A brief account of changes that were 
made to the trial, on what basis they were made, and 
when is important. The fact that the design allows for 
adaptations will inluence interpretation of results, 
potentially due to operational and statistical biases. If 
changes should have been made, but were not, then this 
may further inluence credibility of results. See the main 
checklist item 14c for details. See box 7 for exemplars.
Box 2: Deinitions of key technical terms
ɑValidity—The ability to provide correct statistical inference to establish effects of 
study interventions and produce accurate estimates of effects (point estimates and 
uncertainty), to give results that are convincing to the broader audience (science 
community and consumers of research findings).
ɑIntegrity—Relates to minimisation of operational bias, maintenance of data 
confidentiality, and ensuring consistency in trial conduct (before and after 
adaptations) for credibility, interpretability, and persuasiveness of trial results.
ɑ3UHSODQQHGDGDSWDWLRQVRUDGDSWLYHIHDWXUHV—Pre-planned or prespecified changes 
or modifications to be made to aspects of an ongoing trial, which are specified at the 
design stage or at least before seeing accumulating trial data by treatment group, and 
are documented for audit trail (such as in the protocol).
ɑ8QSODQQHGFKDQJHV—Ad hoc modifications to aspects of an ongoing trial.
ɑ7\SHRI$'—The main category used to classify a trial design by its pre-planned 
adaptive features or adaptations. Some ADs can fall into more than one main 
category of trial adaptation (see table 1).
ɑ$GDSWLYHGHFLVLRQPDNLQJFULWHULD—Elements of decision-making rules describing 
whether, how, and when the proposed trial adaptations will be used during the trial. 
It involves pre-specifying a set of actions guiding how decisions about implementing 
the trial adaptations are made given interim observed data (decision rules). It also 
involves pre-specifying limits or parameters to trigger trial adaptations (decision 
boundaries). For example, stopping boundaries that relate to pre-specified limits 
regarding decisions to stop the trial or treatment arm(s) early.
ɑ,QWHULPDQDO\VLV—A statistical analysis or review of accumulating data from an 
ongoing trial (interim data) to inform trial adaptations (before the final analysis), 
which may or may not involve treatment group comparisons.
ɑ%LQGLQJUXOHV—Decision rules that must be adhered to for the design to control the 
false positive error rate.
ɑ1RQELQGLQJUXOHV—Optional decision rules that can be overruled without negative 
effects on control of the false positive error rate.
ɑ6WDWLVWLFDOSURSHUWLHVRURSHUDWLQJFKDUDFWHULVWLFV—Relates to behaviour of the 
trial design. These may include statistical power, false positive error rate, bias in 
estimation of treatment effect(s), or probability of each adaptation taking place.
ɑ6LPXODWLRQ—A computational procedure performed using a computer program to 
evaluate statistical properties of the design by generating pseudo data according to 
the design, under a number of scenarios and repeated a large number of times.
ɑ)L[HGQRQDGDSWLYHGHVLJQ—A clinical trial that is designed with an expected fixed 
sample size without any scope for pre-planned changes (adaptations) of any study 
design feature.
ɑ%LDV—The systematic tendency for the treatment effect estimates to deviate from 
their “true values”; including the statistical properties (such as error rates) to deviate 
from what is expected in theory (such as pre-specified nominal error rate).
ɑ2SHUDWLRQDOELDV—Occurs when knowledge of key trial-related information influences 
changes to the conduct of that trial in a manner that biases the conclusions made 
regarding the benefits and/or harms of study treatments.
ɑ6WDWLVWLFDOELDV—Bias introduced to the study results or conclusions by the design: 
for example, as a result of changes to aspects of the trial or multiple analyses of 
accumulating data from an ongoing trial.
ɑ6XESRSXODWLRQV—Subset(s) of the trial population that can be classified by 
characteristics of participants that are thought to be associated with treatment 
response (such as genetic markers or biomarkers).
ɑ$GDSWDWLRQRXWFRPHV—Outcome(s) used to guide trial adaptation(s); they may be 
different from the primary outcome(s).
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Section 3: Methods (Trial design)
Ŷ ACE item 3b (new): Type of adaptive design used, 
with details of the pre-planned adaptations and the 
statistical information informing the adaptations
Explanation—A description of the type of AD 
indicates the underlying design concepts and the 
applicable adaptive statistical methods. Although there 
is an inconsistent use of nomenclature to classify ADs, 
together with growing related methodology,13 some 
currently used types of ADs are presented in table 1. A 
clear description will also improve the indexing of AD 
methods and for easy identiication during literature 
reviews.
Speciication of pre-planned opportunities for 
adaptations and their scope is essential to preserve 
the integrity of AD randomised trials22 and for 
regulatory assessments, regardless of whether they 
were triggered during the trial.14 108 109 Details of 
pre-planned adaptations enable readers to assess 
the appropriateness of statistical methods used to 
evaluate operating characteristics of the AD (item 7a) 
and for performing statistical inference (item 12b). 
Unfortunately, pre-planned adaptations are commonly 
insuiciently described.119 Authors are encouraged 
to explain the scientiic rationale for choosing the 
considered pre-planned adaptations encapsulated 
under the CONSORT 2010 item “scientiic background 
and explanation of rationale” (item 2a). This rationale 
should focus on the goals of the considered adaptations 
in line with the study objectives and hypotheses 
(item 2b).107 108 119 123
Details of pre-planned adaptations with rationale 
should be documented in accessible study documents 
for readers to be able to evaluate what was planned 
and unplanned (such as protocol, interim and inal 
SAP or dedicated trial document). Of note, any pre-
planned adaptation that modiies eligibility criteria 
(such as in population enrichment ADs92 146) should be 
clearly described.
Adaptive trials use accrued statistical information 
to make pre-planned adaptation(s) (item 14c) at 
Table 1 | Some types of adaptations used in randomised trials with examples
Trial adaptive feature or adaptation, motivation,  
and cited examples of use
Type of adaptive design (AD) and examples  
of underlying statistical methods
Changing the predetermined sample size in response to  
inaccurate assumptions of study design parameters to  
achieve the desired statistical power.38-40
Sample size re-estimation, re-assessment, or re-calculation (SSR) using  
aggregated interim data from all participants or interim data separated  
according to allocated treatment.41-48
Stopping the trial early for eicacy, futility, or safety when  
there is suicient evidence.49 50
Group sequential design (GSD)51 52; information-based GSD53;  
futility assessment using stochastic curtailment.54-56
Evaluating multiple treatments in one trial allowing for early selection of promising  
treatments or dropping futile or unsafe treatments.57-59 New treatments can also be  
added to an ongoing trial.60
Multi-arm multi-stage (MAMS), dose/treatment-selection,  
drop-the-loser, or pick-the-winner, or add arm.23 61-70
Changing the treatment allocation ratio to favour  
treatments indicating beneicial efects.71 72
Response-adaptive randomisation (RAR).72-77
Investigating multiple research objectives that are traditionally examined in distinct trial 
phases, in one trial under a single protocol.78-80 For instance, addressing learning (selecting 
promising treatments for further testing) and conirmatory objectives in one trial.
Operationally or inferentially seamless AD.67-69 81-83
Adjusting the trial population or selecting patients with certain characteristics that are  
most likely to beneit from investigative treatments.84-87 This may involve incorporating  
statistical information from or adapting on a biomarker.
Population or patient enrichment or biomarker AD.88-92
Changing the primary research hypotheses or objectives or primary  
endpoints.82 93 For example, switching from non-inferiority to superiority.
Adaptive hypotheses.62 94
Switching the allocated treatment of patients to an alternative treatment influenced by ethical 
considerations, for instance, due to lack of beneit or safety issues.
Adaptive treatment-switching.95 96
Combination of at least two types of adaptations.24 40 93 97-102 Multiple ADs such as GSD or drop-the-loser with SSR103;  
inferentially seamless phase 2/3 AD with hypotheses  
selection81 or population enrichment104; biomarker-stratiied with RAR105;  
adaptive platform trials where arms can be added or stopped early.19 24 106
Box 3: ACE guideline scope and general principles
1.  It applies to all randomised clinical trials using an adaptive design (AD), as defined 
in box 1.
2.  It excludes randomised clinical trials that change aspects of an ongoing trial 
based entirely on external information130 or with internal pilots focusing solely 
on feasibility and processes (such as recruitment, intervention delivery, and data 
completeness).131
3.  It covers general reporting principles to make it applicable to a wide range of 
current and future ADs and trial adaptations.
4.  It is not intended to promote or discourage the use of any specific type of AD, trial 
adaptation, or frequentist or Bayesian statistical methods. These choices should 
be driven by the scientific research questions, the goals behind the use of the 
proposed AD features, and practical considerations.22
5.  It aims to promote transparent and adequate reporting of AD randomised trials 
to maximise their potential benefits and improve the interpretability of their 
results and their reproducibility, without impeding their appropriate use or stifling 
design innovation. Therefore, the guideline does not specifically address the 
appropriateness of adaptive statistical methods.
6.  It presents the minimum requirements that should be reported but we also 
encourage authors to report additional information that may enhance the 
interpretation of trial findings.
7.  Access to information is most important regardless of the source and form of 
publication. For example, use of appendices and citation of accessible material 
(such as protocols, statistical analysis plans (SAPs), or related publications) is 
often sufficient.
8.  The order in which researchers report information does not necessarily need to 
follow the order of the checklist.
9.  The guideline does not primarily address specific reporting needs for  
non-randomised ADs (such as phase I dose escalation studies, phase II  
single-arm designs). However, some principles covered here may still apply to  
such trials.
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interim analyses guided by pre-planned decision-
making criteria and rules (item 7b). Reporting this 
statistical information for guiding adaptations and 
how it is gathered is paramount. Analytical derivations 
of statistical information guiding pre-planned 
adaptations using statistical models or formulae 
should be described to facilitate reproducibility and 
interpretation of results. The use of supplementary 
material or references to published literature is 
suicient. For example, sample size re-assessment 
(SSR) can be performed using diferent methods 
with or without knowledge or use of treatment arm 
allocation.41 42 44 48 Around 43% (15/35) of regulatory 
submissions needed further clariications because of 
failure to describe how a SSR would be performed.119 
Early stopping of a trial or treatment group for futility 
can be evaluated based on statistical information to 
support lack of evidence of beneit that is derived and 
expressed in several ways. For example, conditional 
power,56 147-150 predictive power,55 148 151-153 the thre-
shold of the treatment efect, posterior probability 
of the treatment efect,100 or some form of clinical 
utility that quantiies the balance between beneits 
against harms154 155 or between patient and society 
perspectives on health outcomes.100 See box 8 for 
exemplars.
Ŷ CONSORT 2010 item 3b: Important changes to the 
design or methods after trial commencement (such 
as eligibility criteria), with reasons
Ŷ ACE item 3c (modiication, renumbered): Impor-
tant changes to the design or methods after trial 
commencement (such as eligibility criteria) outside 
the scope of the pre-planned adaptive design 
features, with reasons
Explanation—Unplanned changes to certain aspects 
of the design or methods in response to unexpected 
circumstances that occur during the trial are common 
and will need to be reported in AD randomised trials, 
as in ixed design trials. This may include deviations 
from pre-planned adaptations and decision rules,15 
70 as well as changes to timing and frequency of 
interim analyses. Traditionally, unplanned changes 
with explanation have been documented as protocol 
amendments and reported as discussed in the CONSORT 
2010 statement.3 4 Unplanned changes, depending on 
what they are and why they were made, may introduce 
bias and compromise trial credibility. Some unplanned 
changes may render the planned adaptive statistical 
methods invalid or may complicate interpretation 
of results.22 It is therefore essential for authors to 
detail important changes that occurred outside the 
scope of the pre-planned adaptations and to explain 
why deviations from the planned adaptations were 
necessary. Furthermore, it should be clariied whether 
unplanned changes were made following access to 
key trial information such as interim data seen by 
treatment group or interim results. Such information 
will help readers assess potential sources of bias and 
implications for the interpretation of results. For ADs, 
it is essential to distinguish unplanned changes from 
pre-planned adaptations (item 3b).161 See box 9 for an 
exemplar.
Section 6. Outcomes
Ŷ CONSORT 2010 item 6a: Completely deine 
pre-speciied primary and secondary outcome 
measures, including how and when they were 
assessed
Box 4: Summary of signiicant changes to the CONSORT 2010 statement
ɑ1HZLWHPVɇIntroduces seven new items that are specific to AD randomised trials
 ƕ 3b on pre-planned AD features,
 ƕ 11c on confidentiality and minimisation of operational bias,
 ƕ 12b on estimation and inference methods,
 ƕ 14c on adaptation decisions,
 ƕ 15b on similarity between stages,
 ƕ 17c on interim results and,
 ƕ 24b on SAP and other relevant trial documents.
ɑ5HVWUXFWXULQJɇRenumbers four standard items to accommodate the new items
 ƕ 3b is now 3c (on losses and exclusions) to accommodate the new item 3b,
 ƕ 12b is now 12c (on methods for additional analyses) to accommodate the new 
item 12b,
 ƕ 15 on baseline demographics and clinical characteristics is now 15a to 
accommodate new item 15b and,
 ƕ 24 on access to protocol is now 24a to accommodate new item 24b.
ɑ0RGLILHGLWHPVɇModifies nine standard items
 ƕ 3b (now 3c) on important changes to the design or methods after 
commencement,
 ƕ 6a on pre-specified primary and secondary outcomes,
 ƕ 6b on changes to trial outcomes after commencement,
 ƕ 7a on sample size,
 ƕ 7b on interim analyses and stopping rules, which is now a replacement capturing 
adaptive decision-making criteria to guide adaptation(s),
 ƕ 8b on type of randomisation,
 ƕ 12a on statistical methods to compare groups,
 ƕ 13a on participants randomised, treated, and analysed,
 ƕ 14a on dates for recruitment and follow-up.
ɑ([SDQGHGWH[WɇExpands the E&E text for clarification on six items without changes to 
item wording
 ƕ 14b on why the trial ended or was stopped,
 ƕ 15 (now 15a) on baseline demographics and clinical characteristics,
 ƕ 16 on numbers randomised,
 ƕ 17a on primary and secondary outcome results,
 ƕ 20 on limitations and,
 ƕ 21 on generalisability.
ɑ5HVWUXFWXULQJɇRenames two subsection headings to reflect new ACE content
 ƕ “recruitment” renamed to “recruitment and adaptations”
 ƕ “sample size” renamed to “sample size and operating characteristics”
ɑ5HVWUXFWXULQJɇIntroduces a new subsection heading
 ƕ “Statistical analysis plan and other trial-related documents” to accommodate 
item 24b
Modifies abstract item 1b and introduces an extension for journal and conference 
abstracts
ɑ1HZLWHPɇIntroduces one new item (on adaptation decisions made)
 ƕ On “adaptation decisions made”
ɑ0RGLILHGLWHPɇModifies one standard item
 ƕ On “trial design”
ɑ([SDQGHGWH[WɇExpands the E&E text for clarification on one item for certain ADs in 
particular circumstances without changes to item wording
 ƕ On “outcome”
Item numbers or section/topic referenced here are presented in tables 2 and 3.
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Section/ Topic Item No Standard CONSORT 2010 checklist item Extension for adaptive design randomised trials
Page 
No
Title and abstract 1a Identiication as a randomised trial in the title
1b Structured summary of trial design, methods, 
results, and conclusions (for speciic guidance see 
CONSORT for abstracts)136 137
Structured summary of trial design, methods, results, and  
conclusions (for speciic guidance see ACE for abstracts, table 3)
Introduction
Background and objectives 2a Scientiic background and explanation of rationale
2b Speciic objectives or hypotheses
Methods
Trial design 3a Description of trial design (such as parallel, factorial) 
including allocation ratio
3b«* Type of adaptive design used, with details of the pre-planned 
trial adaptations and the statistical information informing the 
adaptations
3c«3b† Important changes to methods ater trial  
commencement (such as eligibility criteria), with 
reasons
Important changes to the design or methods ater trial  
commencement (such as eligibility criteria) outside the scope of 
the pre-planned adaptive design features, with reasons
Participants 4a Eligibility criteria for participants
4b Settings and locations where the data were  
collected
Interventions 5 The interventions for each group with suicient 
details to allow replication, including how and when 
they were actually administered
Outcomes 6a† Completely deined pre-speciied primary and  
secondary outcome measures, including how and 
when they were assessed
Completely deine pre-speciied primary and secondary outcome 
measures, including how and when they were assessed. Any other 
outcome measures used to inform pre-planned adaptations should 
be described with the rationale
6b† Any changes to trial outcomes ater the trial  
commenced, with reasons
Any unplanned changes to trial outcomes ater the trial com-
menced, with reasons
Sample size and operating 
characteristics
7a† How sample size was determined How sample size and operating characteristics were determined
7b‡ When applicable, explanation of any interim  
analyses and stopping guidelines
Pre-planned interim decision-making criteria to guide the trial 
adaptation process; whether decision-making criteria were binding 
or non-binding; pre-planned and actual timing and frequency of 
interim data looks to inform trial adaptations
Randomisation
Sequence generation 8a Method used to generate the random allocation 
sequence
8b† Type of randomisation; details of any restriction 
(such as blocking and block size)
Type of randomisation; details of any restriction (such as blocking 
and block size); any changes to the allocation rule ater trial  
adaptation decisions; any pre-planned allocation rule or algorithm 
to update randomisation with timing and frequency of updates
Allocation concealment 
mechanism
9 Mechanism used to implement the random  
allocation sequence (such as sequentially numbered 
containers), describing any steps taken to conceal 
the sequence until interventions were assigned
Implementation 10 Who generated the random allocation sequence, 
who enrolled participants, and who assigned  
participants to interventions
Blinding 11a If done, who was blinded ater assignment to  
interventions (for example, participants, care  
providers, those assessing outcomes) and how
11b If relevant, description of the similarity  
of interventions
11c* Measures to safeguard the conidentiality of interim information 
and minimise potential operational bias during the trial
Statistical methods 12a† Statistical methods used to compare groups for 
primary and secondary outcomes
Statistical methods used to compare groups for primary and  
secondary outcomes, and any other outcomes used to make  
pre-planned adaptations
12b«* For the implemented adaptive design features, statistical methods 
used to estimate treatment efects for key endpoints and to make 
inferences
12c«12b Methods for additional analyses, such as subgroup 
analyses and adjusted analyses
Results
Participant flow (a diagram is 
strongly recommended)
13a† For each group, the numbers of participants who 
were randomly assigned, received intended  
treatment, and were analysed for the primary 
outcome
For each group, the numbers of participants who were randomly 
assigned, received intended treatment, and were analysed for the 
primary outcome and any other outcomes used to inform  
pre-planned adaptations, if applicable
13b For each group, losses and exclusions ater  
randomisation, together with reasons
Table 2 | ACE checklist for the main report
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Ŷ ACE item 6a (modiication): Completely deine 
pre-speciied primary and secondary outcome 
measures, including how and when they were 
assessed. Any other outcome measures used 
to inform pre-planned adaptations should be 
described with the rationale
Comment—Authors should also refer to the CONSORT 
2010 statement3 4 for the original text when applying 
this item.
Explanation—It is paramount to provide a detailed 
description of pre-speciied outcomes used to assess 
clinical objectives including how and when they were 
assessed. For operational feasibility, ADs often use 
outcomes that can be observed quickly and easily to 
inform pre-planned adaptations (adaptation outcomes). 
Thus, in some situations, adaptations may be based 
on early observed outcome(s)162 that are believed to be 
informative for the primary outcome even though diferent 
from the primary outcome. The adaptation outcome 
(such as a surrogate, biomarker, or an intermediate 
outcome) together with the primary outcome inluences 
the adaptation process, operating characteristics of 
the AD, and interpretation and trustworthiness of trial 
results. Despite many potential advantages of using 
early observed outcomes to adapt a trial, they pose 
additional risks of making misleading inferences if they 
are unreliable.163 For example, a potentially beneicial 
treatment could be wrongly discarded, an inefective 
treatment incorrectly declared efective or wrongly 
carried forward for further testing, or the randomisation 
updated based on unreliable information.
Authors should therefore clearly describe adaptation 
outcomes similar to the description of pre-speciied 
primary and secondary outcomes in the CONSORT 
2010 statement.3 4 Authors are encouraged to provide 
Section/ Topic Item No Standard CONSORT 2010 checklist item Extension for adaptive design randomised trials
Page 
No
Recruitment and adaptations 14a† Dates deining the periods of recruitment and 
follow-up
Dates deining the periods of recruitment and follow-up,  
for each group
14b§ Why the trial ended or was stopped See expanded E&E text for clariication
14c* Specify what trial adaptation decisions were made in light of the 
pre-planned decision-making criteria and observed accrued data
Baseline data 15a«15§ A table showing baseline demographic and clinical 
characteristics for each group
See expanded E&E text for clariication
15b* Summary of data to enable the assessment of similarity in  
the trial population between interim stages
Numbers analysed 16§ For each group, number of participants (denominator) 
included in each analysis and whether the analysis 
was by original assigned groups
See expanded E&E text for clariication
Outcomes and estimation 17a§ For each primary and secondary outcome, results 
for each group, and the estimated efect size and its 
precision (such as 95% conidence interval)
See expanded E&E text for clariication
17b For binary outcomes, presentation of both absolute 
and relative efect sizes is recommended
17c* Report interim results used to inform interim decision-making
Ancillary analyses 18 Results of any other analyses performed, including 
subgroup analyses and adjusted analyses,  
distinguishing pre-speciied from exploratory
Harms 19 All important harms or unintended efects in each 
group (for speciic guidance see CONSORT for 
harms)138
Discussion
Limitations 20§ Trial limitations, addressing sources of potential 
bias, imprecision, and, if relevant, multiplicity of 
analyses
See expanded E&E text for clariication
Generalisability 21§ Generalisability (external validity, applicability) of 
the trial indings
See expanded E&E text for clariication
Interpretation 22 Interpretation consistent with results, balancing 
beneits and harms, and considering other relevant 
evidence
Other information
Registration 23 Registration number and name of trial registry
Protocol 24a«24 Where the full trial protocol can be accessed
SAP and other relevant trial 
documents
24b* Where the full statistical analysis plan and other relevant trial 
documents can be accessed
Funding 25 Sources of funding and other support  
(such as supply of drugs), role of funders
ACE = Adaptive designs CONSORT Extension. E&E = explanation and elaboration. SAP = statistical analysis plan.
“X« Y” means original CONSORT 2010 item Y has been renumbered to X;
“X«” means item reordering resulted in new item X replacing the number of the original CONSORT 2010” item X”;
*New items that should only be applied in reference to ACE;
†Modiied items that require reference to both CONSORT 2010 and ACE;
‡Replacement (modiied) item that only requires reference to ACE;
§Item wording remains unchanged in reference to CONSORT 2010 but we expanded the ACE explanatory text to clarify additional considerations for certain adaptive designs. These unchanged 
items require reference to CONSORT 2010 except for item 14b.
Table 2 | Continued
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a clinical rationale supporting the use of an adaptation 
outcome that is diferent to the primary outcome in 
order to aid the clinical interpretation of results. For 
example, evidence supporting that the adaptation 
outcome can provide reliable information on the 
primary outcome will suice. See box 10 for exemplars.
Ŷ CONSORT 2010 item 6b: Any changes to trial 
outcomes after the trial commenced, with reasons
Ŷ ACE item 6b (modiication): Any unplanned changes 
to trial outcomes after the trial commenced, with 
reasons
Comment—Authors may wish to cross-reference the 
CONSORT 2010 statement3 4 for background details.
Explanation—Outcome reporting bias occurs when 
the selection of outcomes to report is inluenced by 
the nature and direction of results. The prevalence 
of outcome reporting bias in medical research is well 
documented: discrepancies between pre-speciied 
outcomes in protocols or registries and those 
published in reports12 168-171; outcomes that portray 
favourable beneicial efects of treatments and safety 
proiles being more likely to be reported169; some pre-
speciied primary or secondary outcomes modiied or 
switched after trial commencement.170 Changes to trial 
outcomes may also include changes to how outcomes 
were assessed or measured, when they were assessed, 
or the order of importance to address objectives.171
Sometimes when planning trials, there is huge 
uncertainty around the magnitude of treatment efects 
on potential outcomes viewed acceptable as primary 
endpoints.36 171 As a result, although uncommon, a 
pre-planned adaptation could include the choice of 
the primary endpoints or hypotheses for assessing the 
beneit-risk ratio. In such circumstances, the adaptive 
strategy should be clearly described as a pre-planned 
adaptation (item 3b). Authors should clearly report any 
additional changes to outcomes outside the scope of the 
pre-speciied adaptations including an explanation of 
why such changes occurred in line with the CONSORT 
2010 statement. This will enable readers to distinguish 
pre-planned trial adaptations of outcomes from 
unplanned changes, thereby allowing them to judge 
outcome reporting bias. See box 11 for an exemplar.
Section 7. Sample size and operating 
characteristics
Ŷ CONSORT 2010 item 7a: How sample size was 
determined
Ŷ ACE item 7a (modiication): How sample size and 
operating characteristics were determined
Table 3 | ACE checklist for abstracts
Section/Topic Standard checklist description Extension for adaptive design randomised trials
Title Identiication of study as randomised
Authors Contact details for the corresponding author
Trial design* Description of the trial design  
(for example, parallel, cluster, non-inferiority)
Description of the trial design (for example, parallel, cluster, non-inferiority); 
include the word “adaptive” in the content or at least as a keyword
Methods
Participants Eligibility criteria for participants and the  
settings where the data were collected
Interventions Interventions intended for each group
Objective Speciic objective or hypothesis
Outcome† Clearly deined primary outcome for this report See expanded E&E text for clariication
Randomisation How participants were allocated to interventions
Blinding (masking) Whether or not participants, care givers, and those assessing 
the outcomes were blinded to group assignment
Results
Numbers randomised Number of participants randomised to each group
Recruitment Trial status
Adaptation decisions made‡ Specify what trial adaptation decisions were made in light of the pre-planned 
decision-making criteria and observed accrued data
Numbers analysed Number of participants analysed in each group
Outcome For the primary outcome, a result for each group and the 
estimated efect size and its precision
Harms Important adverse events or side efects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
E&E = explanation and elaboration.
*Modiied items that require reference to both CONSORT for abstracts136 137 and ACE;
†Item wording remains unchanged in reference to CONSORT for abstracts,136 137 but we expanded the ACE explanatory text to clarify additional considerations for certain adaptive designs.
‡New items that should only be applied in reference to ACE.
Box 5: Exemplars on the use of “adaptive” in the abstract content and/or as a 
keyword
ɑ([DPSOHʴ $EVWUDFWWLWOH
 ƕ “Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a 
randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian 
adaptive design (the SPRINT trial).”140
ɑ([DPSOHʵ $EVWUDFWEDFNJURXQG
 ƕ “The drug development process can be streamlined by combining the traditionally 
separate stages of dose-finding (Phase IIb) and confirmation of efficacy and 
safety (Phase III) using an adaptive seamless design.”141
ɑ([DPSOHʶ $EVWUDFWDLPVDQGNH\ZRUG
 ƕ “AWARD-5 was an adaptive, seamless, double-blind study comparing 
dulaglutide, a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist, with 
placebo at 26 weeks and sitagliptin up to 104 weeks.” and keyword “Bayesian 
adaptive”97
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Comments—This section heading was modiied to 
relect additional operating characteristics that may be 
required for some ADs in addition to the sample size. 
Items 3b, 7a, 7b, and 12b are connected so they should 
be cross-referenced when reporting.
Explanation—Operating characteristics, which 
relate to the statistical behaviour of a design, 
should be tailored to address trial objectives and 
hypotheses, factoring in logistical, ethical, and clinical 
considerations. These may encompass the maximum 
sample size, expected sample sizes under certain 
scenarios, probabilities of identifying beneicial 
treatments if they exist, and probabilities of making 
false positive claims of evidence.172 173 Speciically, 
the predetermined sample size for ADs is inluenced, 
among other things, by:
1. Type and scope of adaptations considered (item 
3b);
2. Decision-making criteria used to inform adap-
tations (item 7b);
3. Criteria for claiming overall evidence (such as 
based on the probability of the treatment efect 
being above a certain value, targeted treatment 
efect of interest, and threshold for statistical 
signiicance174 175);
4. Timing and frequency of the adaptations (item 
7b);
5. Type of primary outcome(s) (item 6a) and 
nuisance parameters (such as outcome variance);
6. Method for claiming evidence on multiple key 
hypotheses (part of item 12b);
7. Desired operating characteristics (see box 2), 
such as statistical power and an acceptable level 
of making a false positive claim of beneit;
8. Adaptive statistical methods used for analysis 
(item 12b);
9. Statistical framework (frequentist or Bayesian) 
used to design and analyse the trial.
Information that guided estimation of sample size(s), 
including operating characteristics of the considered 
AD, should be described suiciently to enable rea-
ders to reproduce the sample size calculation. The 
assumptions made concerning design parameters 
should be clearly stated and supported with evidence 
if possible. Any constraints imposed (for example, 
due to limited trial population) should be stated. It is 
good scientiic practice to reference the statistical tools 
used (such as statistical software, program, or code) 
and to describe the use of statistical simulations when 
relevant (see item 24b discussion).
In a situation where changing the sample size is a 
pre-planned adaptation (item 3b), authors should 
report the initial sample sizes (at interim analyses 
before the expected change in sample size) and the 
maximum allowable sample size per group and in total 
if applicable. The planned sample sizes (or expected 
numbers of events for time-to-event data) at each 
interim analysis and inal analysis should be reported 
by treatment group and overall. The timing of interim 
analyses can be speciied as a fraction of information 
gathered rather than sample size. See box 12 for 
exemplars.
Ŷ CONSORT 2010 item 7b: When applicable, 
explanation of any interim analyses and stopping 
guidelines
Ŷ ACE item 7b (replacement): Pre-planned interim 
decision-making criteria to guide the trial adap-
tation process; whether decision-making criteria 
were binding or non-binding; pre-planned and 
actual timing and frequency of interim data looks 
to inform trial adaptations
Comments—This item is a replacement so when 
reporting, the CONSORT 20103 item 7b content 
should be ignored. Items 7b and 8b overlap, but we 
intentionally reserved item 8b speciically to enhance 
complete reporting of ADs with randomisation updates 
as a pre-planned adaptation. Reporting of these items 
is also connected to items 3b and 12b.
Explanation—Transparency and complete reporting 
of pre-planned decision-making criteria (box 2) 
and how overall evidence is claimed are essential as 
they inluence operating characteristics of the AD, 
credibility of the trial, and clinical interpretation of 
indings.22 32 182
A key feature of an AD is that interim decisions about 
the course of the trial are informed by observed interim 
data (element of item 3b) at one or more interim 
analyses guided by decision rules describing how and 
when the proposed adaptations will be activated (pre-
planned adaptive decision-making criteria). Decision 
rules, as deined in box 2, may include, but are not 
limited to, rules for making adaptations described in 
table 1. Decision rules are often constructed with input 
of key stakeholders (such as clinical investigators, 
Box 6: Exemplars on reporting outcomes in the abstract
ɑ([DPSOHʴ %D\HVLDQ5$5GRVHILQGLQJ$'ZLWKHDUO\VWRSSLQJIRUHIILFDF\RUIXWLOLW\
 ƕ “The primary outcome required, first, a greater than 90% posterior probability 
that the most promising levocarnitine dose decreases the Sequential Organ 
Failure Assessment (SOFA) score at 48 hours and, second (given having met 
the first condition), at least a 30% predictive probability of success in reducing 
28-day mortality in a subsequent traditional superiority trial to test efficacy.”142
ɑ([DPSOHʵ 6HTXHQWLDOVWHS$'
 ƕ “The primary efficacy endpoint was definitive cure (absence of parasites in tissue 
aspirates) at 6 months. If interim analyses, based on initial cure evaluated 30 
days after the start of treatment…”143
Box 7: Exemplars on reporting adaptation decisions made to the trial in the 
abstract
ɑ([DPSOHʴ ʵ VWDJHLQIHUHQWLDOVHDPOHVVSKDVHʵ ʶ$'SUHSODQQHGDGDSWDWLRQ
GHFLVLRQV
 ƕ “A planned interim analysis was conducted for otamixaban dose selection using 
a pre-specified algorithm (unknown to investigators) … The selected regimen to 
carry forward was an intravenous bolus of 0.080mg/kg followed by an infusion of 
0.140 mg/kg per hour.”144
ɑ([DPSOHʵ *URXSVHTXHQWLDO$'HDUO\VWRSSLQJGHFLVLRQ
 ƕ “The trial was stopped early (at the third interim analysis), according to pre-
specified rules, after a median follow-up of 27 months, because the boundary for 
an overwhelming benefit with LCZ696 had been crossed.”145
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statisticians, patient groups, health economists, and 
regulators).183 For example, statistical methods for 
formulating early stopping decision rules of a trial or 
treatment group(s) exist.51 52 184-187
Decision boundaries (for example, stopping 
boundaries), pre-speciied limits or parameters used 
to determine adaptations to be made, and criteria for 
claiming overall evidence of beneit and/or harm (at an 
interim or inal analysis) should be clearly stated. These 
are inluenced by statistical information used to inform 
adaptations (item 3b). Decision trees or algorithms can 
aid the representation of complex adaptive decision-
making criteria.
Allowing for trial adaptations too early in a trial 
with inadequate information severely undermines 
robustness of adaptive decision-making criteria and 
trustworthiness of trial results.188 189 Furthermore, 
methods and results can only be reproducible when 
timing and frequency of interim analyses are ade-
quately described. Therefore, authors should detail 
when and how often the interim analyses were 
planned to be implemented. The planned timing can 
be described in terms of information such as interim 
sample size or number of events relative to the 
maximum sample size or maximum number of events, 
respectively. For example, in circumstances when the 
pre-planned and actual timing or/and frequency of 
the interim analyses difer, reports should clearly state 
what actually happened (item 3c).
Box 8: Exemplars on reporting item 3b elements
ɑ([DPSOHʴ 3UHSODQQHGDGDSWDWLRQVDQGUDWLRQDOHLQIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶ$'
 ƕ “The adaptive (inferentially) seamless phase II/III design is a novel approach to drug development that combines phases II and III in a single, 
two-stage study. The design is adaptive in that the wider choice of doses included in stage 1 is narrowed down to the dose(s) of interest to be 
evaluated in stage 2. The trial is a seamless experience for both investigators and patients in that there is no interruption of ongoing study 
treatment between the two phases. Combining the dose-finding and confirmatory phases of development into a single, uninterrupted study has 
the advantages of speed, efficiency and flexibility15 17… The primary aim of stage 1 of the study was to determine the risk-benefit of four doses of 
indacaterol (based on efficacy and safety results in a pre-planned interim analysis) in order to select two doses to carry forward into the second 
stage of the study.”141
ɑ([DPSOHʵ $QDO\WLFDOGHULYDWLRQRIVWDWLVWLFDOLQIRUPDWLRQWRJXLGHDGDSWDWLRQVSRSXODWLRQHQULFKPHQW$'ZLWK665
 ƕ Mehta et al99 detail formulae used to calculate the conditional power to guide modification of the sample size or to enrich the patient population 
at an interim analysis for both cutaneous and non-cutaneous patients (full population) and only cutaneous patients (subpopulation) in the 
supplementary material. In addition, the authors detail formulae used to derive associated conditional powers and p-values used for decision-
making to claim evidence of benefit both at the interim and final analysis (linked to item 12b).
ɑ([DPSOHʶ 3UHSODQQHGDGDSWDWLRQVʸ DUPʵ VWDJH$'DOORZLQJIRUUHJLPHQVHOHFWLRQHDUO\VWRSSLQJIRUIXWLOLW\DQG665
 ƕ “This randomized, placebo-controlled, double-blind, phase 2/3 trial had a two-stage adaptive design, with selection of the propranolol regimen 
(dose and duration) at the end of stage 1 (interim analysis) and further evaluation of the selected regimen in stage 2.67 68 Pre-specified possible 
adaptations to be made after the interim analysis, as outlined in the protocol and statistical analysis plan (accessible via journal website), were 
selection of one or two regimens, sample-size reassessment, and non-binding stopping for futility.”98
ɑ([DPSOHʷ 7\SHRI$'SUHSODQQHGDGDSWDWLRQVDQGUDWLRQDOH%D\HVLDQDGDSWLYHHQULFKPHQW$'DOORZLQJIRUHQULFKPHQWDQGHDUO\VWRSSLQJIRU
IXWLOLW\RUHIILFDF\
 ƕ “The DAWN trial was a multicenter, prospective, randomized, open-label trial with a Bayesian adaptive–enrichment design and with blinded 
assessment of endpoints.12 The adaptive trial design allowed for a sample size ranging from 150 to 500 patients. During interim analyses, the 
decision to stop or continue enrolment was based on a pre-specified calculation of the probability that thrombectomy plus standard care would 
be superior to standard care alone with respect to the first primary endpoint (described in the paper). The enrichment trial design gave us the 
flexibility to identify whether the benefit of the trial intervention was restricted to a subgroup of patients with relatively small infarct volumes at 
baseline. The interim analyses, which included patients with available follow-up data at the time of the analysis, were pre-specified to test for 
the futility, enrichment, and success of the trial.”100 See supplementary appendix via journal website (from page 39) for details.
ɑ([DPSOHʸ 5DWLRQDOHW\SHRI$'DQGSUHSODQQHGDGDSWDWLRQVLQIRUPDWLRQWRLQIRUPDGDSWDWLRQVLQIRUPDWLRQEDVHG*6'
 ƕ “Because little was known about the variability of LVMI changes in CKD during the planning stage, we prospectively implemented an 
information-based (group sequential) adaptive design that allowed sample size re-estimation when 50% of the data were collected.50 156”157 
Pritchett et al50 provide details of the pre-planned adaptations and statistical information used to inform SSR and efficacy early stopping.
ɑ([DPSOHʹ 3UHSODQQHGDGDSWDWLRQDQGLQIRUPDWLRQIRU665
 ƕ “To reassess the sample size estimate, the protocol specified that a treatment-blinded interim assessment of the standard deviation (SD) about 
the primary endpoint (change from baseline in total exercise treadmill test duration at trough) would be performed when 231 or one half of the 
planned completed study patients had been randomized and followed up for 12 weeks. The recalculation of sample size, using only blinded 
data, was adjusted based on the estimated SD of the primary efficacy parameter (exercise duration at trough) from the aggregate data…158-160”38
Box 9: Exemplar on reporting item 3c elements
ɑ([DPSOH,QIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶʸDUPʵ VWDJH$'DOORZLQJIRUUHJLPHQ
VHOHFWLRQ665DQGIXWLOLW\HDUO\VWRSSLQJ
 ƕ Although this should ideally have been referenced in the main report, Léauté-
Labrèze et al98 (on pages 17-18 of supplementary material) summarise important 
changes to the trial design including an explanation and discussion of implications. 
These changes include a reduction in the number of patients assigned to the 
placebo across stages—randomisation was changed from 1:1:1:1:1 to 2:2:2:2:1 
(each of the 4 propranolol regimens: placebo) for stage 1 and from 1:1 to 2:1 for 
stage 2 in favour of the selected regimen; revised complete or nearly complete 
resolution success rates for certain treatment regimens. As a result, total sample 
size was revised to 450 (excluding possible SSR); and a slight increase in the 
number of patients (from 175 to 180) to be recruited for the interim analysis.
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Clariication should be made on whether decision 
rules were binding or non-binding to help assess 
implications in the case when they were overruled or 
ignored. For example, when a binding futility boundary 
is overruled and a trial is continued, this would lead to 
a type I error inlation. Non-binding decision rules are 
those that can be overruled without having a negative 
efect on the control of the type I error rate. Use of non-
binding futility boundaries is often advised.55 See box 
13 for exemplars.
Additional examples on the use of non-binding 
futility boundaries and a cap on sample size following 
SSR and treatment selection are given in Appendix B.
Section 8. Randomisation (Sequence generation)
Ŷ CONSORT 2010 item 8b: Type of randomisation; 
details of any restriction (such as blocking and 
block size)
Ŷ ACE item 8b (modiication): Type of randomisation; 
details of any restriction (such as blocking and block 
size); any changes to the allocation rule after trial 
adaptation decisions; any pre-planned allocation 
rule or algorithm to update randomisation with 
timing and frequency of updates
Comments—In applying this item, the reporting 
of randomisation aspects before activation of trial 
adaptations must adhere to CONSORT 2010 items 8a 
and 8b. This E&E document only addresses additional 
randomisation aspects that are essential when 
reporting any AD where the randomisation allocation 
changes. Note that the contents of extension items 7b 
and 8b overlap.
Explanation—In AD randomised trials, the allocation 
ratio(s) may remain ixed throughout or change du- 
ring the trial as a consequence of pre-planned 
adaptations (for example, when modifying rando-
misation to favour treatments more likely to show 
beneits, after treatment selection, or upon introduction 
of a new arm to an ongoing trial).73 Unplanned changes 
may also change allocation ratios (for example, after 
early stopping of a treatment arm due to unforeseeable 
harms).
This reporting item is particularly important for 
response-adaptive randomisation (RAR) ADs as 
several factors inluence their eiciency and opera-
ting characteristics, which in turn inluence the 
trustworthiness of results and necessitate adequate 
reporting.13 196-199 For RAR ADs, authors should 
therefore detail the pre-planned:
Box 10: Exemplars on reporting item 6a elements
ɑ([DPSOHʴ 665GHVFULSWLRQRIWKHDGDSWDWLRQDQGSULPDU\RXWFRPHV
 ƕ “The primary endpoint is a composite of survival free of debilitating stroke (modified Rankin score >3) or the need for a pump exchange. The 
short-term endpoint will be assessed at 6 months and the long-term endpoint at 24 months (primary). Patients who are urgently transplanted 
due to a device complication before a pre-specified endpoint will be considered study failures. All other transplants or device explants due to 
myocardial recovery that occur before a pre-specified endpoint will be considered study successes ... The adaptation was based on interim 
short-term outcome rates.”164
ɑ([DPSOHʵ 6HDPOHVVSKDVHʵ ʶ%D\HVLDQ$'ZLWKWUHDWPHQWVHOHFWLRQGHWDLOVRIDGDSWDWLRQRXWFRPHV
 ƕ “Four efficacy and safety measures were considered important for dose selection based on early phase dulaglutide data: HbA1c, weight, pulse 
rate and diastolic blood pressure (DBP).165 These measures were used to define criteria for dose selection. The selected dulaglutide dose(s) had 
to have a mean change of ≤+5 beats per minute (bpm) for PR and ≤+2 mmHg for DBP relative to placebo at 26 weeks. In addition, if a dose was 
weight neutral versus placebo, it had to show HbA1c reduction ≥1.0% and/or be superior to sitagliptin at 52 weeks. If a dose reduced weight 
relative to placebo ≥2.5 kg, then non-inferiority to sitagliptin would be acceptable. A clinical utility index was incorporated in the algorithm to 
facilitate adaptive randomization and dose selection154 166 based on the same parameters used to define dose-selection criteria described 
above (not shown here).”97
ɑ([DPSOHʶ 6HDPOHVVSKDVHʵ ʶ$'ZLWKWUHDWPHQWVHOHFWLRQGHWDLOVRIDGDSWDWLRQRXWFRPHV
 ƕ “For the dose selection, the joint primary efficacy outcomes were the trough FEV
1
 on Day 15 (mean of measurements at 23 h 10 min and 23 h 45 
min after the morning dose on Day 14) and standardized (average) FEV
1
 area under the curve (AUC) between 1 and 4 h after the morning dose on 
Day 14 (FEV
1
AUC
1–4h
), for the treatment comparisons detailed below (not shown here).”141
ɑ([DPSOHʷ 0$06$'DGDSWDWLRQUDWLRQDOHSDUWRILWHPʶ EUDWLRQDOHIRUDGDSWLRQRXWFRPHGLIIHUHQWIURPWKHSULPDU\RXWFRPHGHVFULSWLRQRIWKH
DGDSWDWLRQDQGSULPDU\RXWFRPHV
 ƕ “This seamless phase 2/3 design starts with several trial arms and uses an intermediate outcome to adaptively focus accrual away from the 
less encouraging research arms, continuing accrual only with the more active interventions. The definitive primary outcome of the STAMPEDE 
trial is overall survival (defined as time from randomisation to death from any cause). The intermediate primary outcome is failure-free survival 
(FFS) defined as the first of: PSA failure (PSA >4 ng/mL and PSA >50% above nadir); local progression; nodal progression; progression of existing 
metastases or development of new metastases; or death from prostate cancer. FFS is used as a screening method for activity on the assumption 
that any treatment that shows an advantage in overall survival will probably show an advantage in FFS beforehand, and that a survival advantage 
is unlikely if an advantage in FFS is not seen. Therefore, FFS can be used to triage treatments that are unlikely to be of sufficient benefit. It is not 
assumed that FFS is a surrogate for overall survival; an advantage in FFS might not necessarily translate into a survival advantage.”167
Box 11: Exemplar on reporting item 6b
ɑ([DPSOH%D\HVLDQDGDSWLYHHQULFKPHQW$'XQSODQQHGFKDQJHIURPDVHFRQGDU\WR
DFRSULPDU\RXWFRPHUDWLRQDOHDQGZKHQLWKDSSHQHG
 ƕ “The second primary endpoint was the rate of functional independence (defined 
as a score of 0, 1, or 2 on the modified Rankin scale) at 90 days. This endpoint was 
changed from a secondary endpoint to a co-primary endpoint at the request of the 
Food and Drug Administration at 30 months after the start of the trial, when the 
trial was still blinded.”100
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Box 12: Exemplars on reporting item 7a elements
ɑ([DPSOHʴ 0$06$'DVVXPSWLRQVDQGDGDSWLYHPHWKRGVDSSURDFKIRUFODLPLQJHYLGHQFHRULQIRUPLQJDGDSWDWLRQVVWDWLVWLFDOSURJUDP
 ƕ “The primary response (outcome) from each patient is the difference between the baseline HOMA-IR score and their HOMA-IR score at 24 weeks. 
The sample size calculation is based on a one-sided type I error of 5% and a power of 90%. If there is no difference between the mean response 
on any treatment and that on control, then a probability of 0.05 is set for the risk of erroneously ending the study with a recommendation that any 
treatment be tested further. For the power, we adopt a generalisation of this power requirement to multiple active treatments due to Dunnett.176 
Effect sizes are specified as the percentage chance of a patient on active treatment achieving a greater reduction in HOMA-IR score than a 
patient on control as this specification does not require knowledge of the common SD, σ. The requirement is that, if a patient on the best active 
dose has a 65% chance of a better response than a patient on control, while patients on the other two active treatments have a 55% chance of 
showing a better response than a patient on control, then the best active dose should be recommended for further testing with 90% probability. 
A 55% chance of achieving a better response on active dose relative to control corresponds to a reduction in mean HOMA-IR score of about a 
sixth of an SD (0.178σ), while the clinically relevant effect of 65% corresponds to a reduction of about half an SD (0.545σ). The critical values for 
recommending that a treatment is taken to further testing at the interim and final analyses (2.782 and 2.086) have been chosen to guarantee 
these properties using a method described by Magirr et al,177 generalising the approach of Whitehead and Jaki.178 The maximum sample size of 
this study is 336 evaluable patients (84 per arm), although the use of the interim analysis may change the required sample size. The study will 
recruit additional patients to account for an anticipated 10% dropout rate (giving a total sample size of 370). An interim analysis will take place 
once the primary endpoint is available for at least 42 patients on each arm (i.e., total of 168, half of the planned maximum of 336 patients). 
Sample size calculation was performed using the MAMS package in R179.”57
ɑ([DPSOHʵ ʶ DUPʵ VWDJH$'ZLWKGRVHVHOHFWLRQJURXSVHTXHQWLDODSSURDFKDVVXPSWLRQVDGDSWDWLRQGHFLVLRQPDNLQJFULWHULDVWDJHʴ DQGʵ 
VDPSOHVL]HVXVHRIVLPXODWLRQV
 ƕ “Sample size calculations are based on the primary efficacy variable (composite of all-cause death or new MI through day 7), with the following 
assumptions: an event rate in the control group of 5.0%, based on event rates from the phase II study (24); a relative risk reduction (RRR) of 
25%; a binomial 1-sided (α=0.025) superiority test for the comparison of 2 proportions with 88% power; and a 2-stage adaptive design with 
one interim analysis at the end of stage 1 data (35% information fraction) to select 1 otamixaban dose for continuation of the study at stage 
2. Selection of the dose for continuation was based on the composite end point of all-cause death, Myocardial Infarction (MI), thrombotic 
complication, and the composite of Thrombosis in Myocardial Infarction (TIMI) major bleeding through day 7, with an assumed probability 
for selecting the “best” dose according to the primary endpoint (r=0.6), a group sequential approach with futility boundary of relative risk of 
otamixaban versus UFH plus eptifibatide ≥1.0, and efficacy boundary based on agamma (−10) α spending function.180 Based on the above 
assumptions, simulations (part of LWHPʵ ʷE, see supplementary material) showed that 13 220 patients (a total of 5625 per group for the 2 
remaining arms for the final analysis) are needed for this study.”181 See figure 1.
Moderate to high risk NSTE-ACS with planned early
invasive strategy.
Total sample size: (N~13 220)
Otamixaban
0.08+0.100
(n=1969)
Randomisation
n=1969 n=1969
Interim analysis
Final analysis
One selected dose goes forward
n=1969
Total: (N=5625)
Extra aer interim
analysis: (n=3656)
Otamixaban
0.08+0.140
(n=1969)
UFH +
Eptifibatide
(n=1969)
Total: (N=5625)
Extra aer interim
analysis: (n=3656)
Fig 1 | Adapted from Steg et al.197
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a. Burn-in period before activating randomisation 
updates, including the period when the control 
group allocation ratio was ixed;
b. Type of randomisation method with allocation 
ratios per group during the burn-in period as 
detailed in the standard CONSORT 2010 item 
8b;
c. Method or algorithm used to adapt or modify 
the randomisation allocations after the burn-in 
period;
d. Information used to inform the adaptive rando-
misation algorithm and how it was derived (item 
3b). Speciically, when a Bayesian RAR is used, we 
encourage authors to provide details of statistical 
Box 13: Exemplars on reporting item 7b elements
ɑ([DPSOHʴ ʵ DUPʵ VWDJH$'ZLWKRSWLRQVIRUHDUO\VWRSSLQJIRUIXWLOLW\RUVXSHULRULW\DQGWRLQFUHDVHWKHVDPSOHVL]HELQGLQJVWRSSLQJUXOHV
 ƕ “To calculate the number of patients needed to meet the primary endpoint, we expected a 3-year overall survival rate of 25% in the group 
assigned to preoperative chemotherapy (arm A) (based on two previous trials190 191). In comparison, an increase of 10% (up to 35%) was 
anticipated by preoperative CRT. Using the log-rank test (one-sided at this point) at a significance level of 5%, we calculated to include 197 
patients per group to ensure a power of 80%. In the first stage of the planned two-stage adaptive design,192 the study was planned to be 
continued on the basis of a new calculation of patients needed if the comparison of patient groups will be 0.0233< p
1
< 0.5. Otherwise, the study 
may be closed for superiority (p
1
< 0.0233) or shall be closed for futility (p
1
≥ 0.5). There was no maximum sample size cap and stopping rules were 
binding.”193 Values p
1
 and p
2
 are p-values derived from independent stage 1 and stage 2 data, respectively. Evidence of benefit will be claimed if 
the overall two-stage p-value derived from p
1
 and p
2
 is ≤0.05.
ɑ([DPSOHʵ 7LPLQJDQGIUHTXHQF\RILQWHULPDQDO\VHVSODQQHGVWRSSLQJERXQGDULHVIRUVXSHULRULW\DQGIXWLOLW\. See table 4
ɑ([DPSOHʶ 3ODQQHGWLPLQJDQGIUHTXHQF\RILQWHULPDQDO\VHVSUHVSHFLILHGGRVHVHOHFWLRQUXOHVIRUDQLQIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶʺDUP
ʵVWDJH$'
 ƕ “The interim analysis was pre-planned for when at least 110 patients per group (770 total) had completed at least 2 weeks of treatment. The 
dose selection guidelines were based on efficacy and safety. The mean effect of each indacaterol dose versus placebo was judged against 
pre-set efficacy reference criteria for trough FEV
1
 and FEV
1
AUC
1–4h
. For trough FEV
1
, the reference efficacy criterion was the highest value of: (a) 
the difference between tiotropium and placebo, (b) the difference between formoterol and placebo, or (c) 120 mL (regarded as the minimum 
clinically important difference). For standardized FEV
1
AUC
1–4h
, the reference efficacy criterion was the highest value of: (a) the difference 
between tiotropium and placebo or (b) the difference between formoterol and placebo. If more than one indacaterol dose exceeded both the 
efficacy criteria, the lowest effective dose plus the next higher dose were to be selected. Data on peak FEV
1
, % change in FEV
1
, and FVC were also 
supplied to the DMC for possible consideration, but these measures were not part of the formal dose selection process and are not presented 
here. The DMC also took into consideration any safety signals observed in any treatment arm.”141
ɑ([DPSOHʷ 7LPLQJDQGIUHTXHQF\RILQWHULPDQDO\VHVGHFLVLRQPDNLQJFULWHULDIRUSRSXODWLRQHQULFKPHQWDQGVDPSOHVL]HLQFUHDVH
 ƕ “Cohort 1 will enrol a total of 120 patients and followed them until 60 PFS events are obtained. At an interim analysis based on the first 40 PFS 
events, an independent data monitoring committee will compare the conditional power for the full population (CP
F
) and the conditional power 
for the cutaneous subpopulation (CP
S
). The formulae for these conditional powers are given in the supplementary appendix (SDUWRILWHPʶ E
H[DPSOHʵ ER[ʻ ). (a) If CP
F
 <0.3 and CP
S
 <0.5, the results are in the unfavourable zone; the trial will enrol 70 patients to cohort 2 and follow them 
until 35 PFS events are obtained (then test effect in the full population). (b) If CP
F
 <0.3 and CP
S
 >0.5, the results are in the enrichment zone; the 
trial will enrol 160 patients with cutaneous disease (subpopulation) to cohort 2 and follow them until 110 PFS events have been obtained from 
the combined patients in both cohorts with cutaneous disease only (then test effect only in the cutaneous subpopulation). (c) If 0.3≤ CP
F
 ≤0.95, 
the results are in the promising zone (so increase sample size); the trial will enrol 220 patients (full population) to cohort 2 and follow them up 
until 110 PFS events are obtained (then test effect in the full population). (d) If CP
F
 >0.95, the results are in the favourable zone; the trial will enrol 
70 patients to cohort 2 and follow them until 35 PFS events are obtained (then test effect in full population).”99 See figure 2 of Mehta et al99 for a 
decision-making tree.
ɑ([DPSOHʸ %D\HVLDQ*6'ZLWKIXWLOLW\HDUO\VWRSSLQJIUHTXHQF\DQGWLPLQJRILQWHULPDQDO\VHVDGDSWDWLRQGHFLVLRQPDNLQJFULWHULDFULWHULDIRU
FODLPLQJWUHDWPHQWEHQHILW
 ƕ “We adopted a group-sequential Bayesian design197 with three stages, of 40 patients each (in total), and two interim analyses after 40 and 80 
randomised participants, and a final analysis after a maximum of 120 randomised participants. We decided that the trial should be stopped 
early if there is a high (posterior) probability (90% or greater) (LWHPʶ E details) that the 90-day survival odds ratio (OR) falls below 1 (i.e. REBOA 
is harmful) at the first or second interim analysis. REBOA will be declared “successful” if the probability that the 90-day survival OR exceeds 1 at 
the final analysis is 95% or greater.”195
Table 4 | Stopping boundaries
Interim analysis Number of primary outcome events (information fraction)
Stopping boundaries
Superiority Futility
Hazard ratio P-value Hazard ratio P-value
1 800 (50%) <0.768 <0.0002 >0.979 >0.758
2 1200 (75%) <0.806 <0.0002 >0.931 >0.216
Final 1600 (100%) <0.906 <0.0500
Adapted from Pocock et al194; primary outcome events are cardiovascular deaths, myocardial infarction, or ischaemic stroke.
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models and rationale for the prior distribution 
chosen;
e. Frequency of updating the allocation ratio (for 
example, after accrual of a certain number of 
participants with outcome data or deined regular 
time period) and;
f. Adaptive decision-making criteria to declare early 
evidence in favour or against certain treatment 
groups (part of item 7b).
In addition, any envisaged changes to the allocation 
ratio as a consequence of other trial adaptations (for 
example, early stopping of an arm or addition of a new 
arm) should be stated. See box 14 for exemplars.
Section 11. Randomisation (Blinding)
Ŷ ACE item 11c (new): Measures to safeguard the 
conidentiality of interim information and minimise 
potential operational bias during the trial
Explanation—Preventing or minimising bias is central 
for robust evaluation of the beneicial and harmful 
efects of interventions. Analysis of accumulating trial 
data brings challenges regarding how knowledge or 
leakage of information, or mere speculation about 
interim treatment efects, may inluence behaviour 
of key stakeholders involved in the conduct of the 
trial.22 122 200 Such behavioural changes may include 
diferential clinical management; reporting of harmful 
efects; clinical assessment of outcomes; and decision-
making to favour one treatment group over the other. 
Inconsistencies in trial conduct before and after 
adaptations have wide implications that may afect 
trial validity and integrity.22 For example, use of 
statistical methods that combine data across stages 
may become questionable or may make overall results 
uninterpretable. AD randomised trials whose integrity 
was severely compromised by disclosure of interim 
results have resulted in regulators questioning the 
credibility of conclusions.201 202 Most AD randomised 
trials, 76% (52/68)49 and 60% (151/251),112 did not 
disclose methods to minimise potential operational 
bias during interim analyses. The seriousness of 
this potential risk will depend on various trial 
characteristics, and the purpose of having disclosure is 
to enable readers to judge the risk of potential sources 
of bias, and thus judge how trustworthy they can 
assume results to be.
The literature covers processes and procedures 
which could be considered by researchers to preserve 
conidentiality of interim results to minimise potential 
operational bias.45 123 203 There is no universal approach 
that suits every situation due to factors such as 
feasibility; nature of the trial; and available resources 
and infrastructure. Some authors discuss roles and 
activities of independent committees in adaptive 
decision-making processes and control mechanisms 
for limiting access to interim information.203-205
Description of the process and procedures put in place 
to minimise the potential introduction of operational 
bias related to interim analyses and decision-making 
to inform adaptations is essential.22 125 203 Speciically, 
authors should give consideration to:
a. Who recommended or made adaptation decisions. 
The roles of the sponsor or funder, clinical 
investigators, and trial monitoring committees 
(for example, independent data monitoring 
committee or dedicated committee for adaptation) 
in the decision-making process should be clearly 
stated;
b. Who had access to interim data and performed 
interim analyses;
c. Safeguards which were in place to maintain 
conidentiality (for example, how the interim 
Box 14: Exemplars on reporting item 8b elements
ɑ([DPSOHʴ 3UHSODQQHGFKDQJHVWRDOORFDWLRQUDWLRVDVDFRQVHTXHQFHRIWUHDWPHQWVHOHFWLRQRUDQGVDPSOHVL]HLQFUHDVH
 ƕ “All new patients recruited after the conclusions of the interim analysis are made, will be randomised in a (2:) 2: 1 ratio to the selected 
regimen(s) of propranolol or placebo until a total of (100:)100: 50 patients (or more in the case where a sample size increase is recommended) 
have been randomised over the two stages of the study.”98 Extracted from supplementary material. (2:) and (100:) are only applicable if the 
second best regimen is selected at stage 1.
ɑ([DPSOHʵ %D\HVLDQ5$5SUHSODQQHGDOJRULWKPWRXSGDWHDOORFDWLRQUDWLRVIUHTXHQF\RIXSGDWHVDIWHUHYHU\SDUWLFLSDQWQREXUQLQSHULRG
SHULRGRIDIL[HGFRQWURODOORFDWLRQUDWLRLQIRUPDWLRQWKDWLQIRUPHGDGDSWDWLRQGHFLVLRQPDNLQJFULWHULDIRUGURSSLQJWUHDWPHQWVSDUWRILWHPʺ E
 ƕ See Appendix C as extracted from Giles et al.71
ɑ([DPSOHʶ %D\HVLDQ5$5EXUQLQSHULRGIL[HGFRQWURODOORFDWLRQUDWLRGHWDLOVRIDGDSWLYHUDQGRPLVDWLRQLQFOXGLQJDGGLWLRQDODGDSWDWLRQVDQG
GHFLVLRQPDNLQJFULWHULDSDUWRILWHPʺ EGHULYDWLRQRIVWDWLVWLFDOTXDQWLWLHVGHWDLOVRI%D\HVLDQPRGHOVDQGSULRUGLVWULEXWLRQZLWKUDWLRQDOH
 ƕ “…eligible patients were randomized on day 1 to treatment with placebo or neublastin 50, 150, 400, 800, or 1200 mg/kg, administered by 
intravenous injection on days 1, 3, and 5. The first 35 patients were randomized in a 2:1:1:1:1:1 ratio to placebo and each of the 5 active doses 
(randomisation method required) (i.e., 10 patients in the placebo group and 5 for each dose of active treatment). Subsequently, 2 of every 7 
enrolled patients were assigned to placebo. Interim data evaluations of pain (AGPI) and pruritus questionnaire data (proportion of patients 
who reported ‘the itch is severe enough to cause major problems for me’ on an Itch Impact Questionnaire) were used to update the allocation 
probability according to a Bayesian algorithm for adaptive allocation and to assess efficacy and futility criteria for early stopping of enrolment 
(fig. 1 [not shown here]). Interim evaluations and updates to the allocation probabilities were performed weekly. Enrolment was to be stopped 
early after ≥50 patients had been followed for 4 weeks if either the efficacy criterion (>80% probability that the maximum utility dose reduces the 
pain score by ≥1.5 points more than the placebo) or the futility criterion (<45% probability that the maximum utility dose reduces pain more than 
the placebo) was met.”140 Details of statistical models used—including computation of posterior quantities; prior distribution with rationale; 
generation of the utility function; and weighting of randomisation probabilities—are accessible via a weblink provided (https://links.lww.com/
PAIN/A433).
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results were communicated and to whom and 
when).
See box 15 for exemplars.
Section 12. Statistical methods
Ŷ CONSORT 2010 item 12a: Statistical methods 
used to compare groups for primary and secondary 
outcomes
Ŷ ACE item 12a (modiication): Statistical methods 
used to compare groups for primary and secondary 
outcomes, and any other outcomes used to make 
pre-planned adaptations
Comment—This item should be applied with 
reference to the detailed discussion in the CONSORT 
2010 statement.3 4
Explanation—The CONSORT 2010 statement3 4 add-
resses the importance of detailing statistical methods 
to analyse primary and secondary outcomes at the 
end of the trial. This ACE modiied item extends this 
to require similar description to be made of statistical 
methods used for interim analyses. Furthermore, 
statistical methods used to analyse any other 
adaptation outcomes (item 6) should be detailed to 
enhance reproducibility of the adaptation process and 
results. Authors should focus on complete description 
of statistical models and aspects of the estimand of 
interest206 207 consistent with stated objectives and 
hypotheses (item 2b) and pre-planned adaptations 
(item 3b).
For Bayesian ADs, item 12b (paragraph 6) describes 
similar information that should be reported for 
Bayesian methods.
See box 16 for exemplars.
Ŷ ACE item 12b (new): For the implemented adaptive 
design features, statistical methods used to 
estimate treatment efects for key endpoints and to 
make inferences
Comments—Note that items 7a and 12b are 
connected. Key endpoints are all primary endpoints as 
well as other endpoints considered highly important, 
for example, an endpoint used for adaptation.
Explanation—A goal of every trial is to provide 
reliable estimates of the treatment efect for assessing 
beneits and risks to reach correct conclusions. 
Several statistical issues may arise when using an AD 
depending on its type and the scope of adaptations, 
the adaptive decision-making criteria and whether 
frequentist or Bayesian methods are used to design and 
analyse the trial.22 Conventional estimates of treatment 
efect based on ixed design methods may be unreliable 
when applied to ADs (for example, may exaggerate the 
patient beneit).96 209-213 Precision around the estimated 
treatment efects may be incorrect (for example, the 
width of conidence intervals may be incorrect). Other 
methods available to summarise the level of evidence 
in hypothesis testing (for example, p-values) may 
give diferent answers. Some factors and conditions 
that inluence the magnitude of estimation bias have 
Box 15: Exemplars on reporting item 11c elements
ɑ([DPSOHʴ ,QIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶ$'
 ƕ “The interim analysis was carried out by an independent statistician (from ClinResearch GmbH, Köln, Germany), who was the only person 
outside the Data Monitoring Committee (DMC) with access to the semi-blinded randomization (sic) codes (treatment groups identified by letters 
A to G). This statistician functioned independently of the investigators, the sponsor’s clinical trial team members and the team that produced 
statistical programming for the interim analysis (DATAMAP GmbH, Freiburg, Germany). The independent statistician was responsible for all 
analyses of efficacy and safety data for the interim analysis. The DMC was given semi-blinded results with treatment groups identified by the 
letters A to G, with separate decodes sealed in an envelope to be opened for decision-making. The personnel involved in the continuing clinical 
study were told which two doses had been selected, but study blinding remained in place and the results of the interim analysis were not 
communicated. No information on the effects of the indacaterol doses (including the two selected) was communicated outside the DMC.”141
ɑ([DPSOHʵ %D\HVLDQLQIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶ$'ZLWK5$5
 ƕ “An independent Data Monitoring Committee (DMC) external to Lilly provided oversight of the implementation of the adaptive algorithm and 
monitored study safety. The DMC fulfilled this role during the dose-finding portion, and continued monitoring after dose selection until an 
interim database lock at 52 weeks, at which time the study was unblinded to assess the primary objectives. Sites and patients continued to be 
blinded to the treatment allocation until the completion of the study. The DMC was not allowed to intervene with the design operations. A Lilly 
Internal Review Committee (IRC), independent of the study team, would meet if the DMC recommended the study to be modified. The role of the 
IRC was to make the final decision regarding the DMC’s recommendation. The external Statistical Analysis Center (SAC) performed all interim 
data analyses for the DMC, evaluated the decision rules and provided the randomization updates for the adaptive algorithm. The DMC chair and 
the lead SAC statistician reviewed these (interim) reports and were tasked to convene an unscheduled DMC meeting if an issue was identified 
with the algorithm or the decision point was triggered.”97
ɑ([DPSOHʶ ,QIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶ$'ZLWKWUHDWPHQWVHOHFWLRQ665DQGQRQELQGLQJIXWLOLW\VWRSSLQJ
 ƕ “Following the interim analysis of the data and the review of initial study hypotheses, the committee (IDMC) chairman will recommend in writing 
to the sponsor whether none, one or two regimen(s) of propranolol is (are) considered to be the ‘best’ (the most efficacious out of all regimens 
with a good safety profile) for further study in stage two of the design. The second ‘best’ regimen will only be chosen for further study along with 
the ‘best’ regimen if the first stage of the study suggests that recruitment in the second stage will be too compromised by the fact that 1 in 3 
patients are assigned to placebo. The IDMC will not reveal the exact sample size increase in the recommendation letter in order to avoid potential 
sources of bias (only the independent statistician, the randomisation team and the IP suppliers will be informed of the actual sample size 
increase). Any safety concerns will also be raised in the IDMC recommendation letter. The chairman will ensure that the recommendations do not 
unnecessarily unblind the study. In the case where the sponsor decides to continue the study, the independent statistician will communicate to 
the randomisation team which regimen(s) is (are) to be carried forward.”98 Extracted from supplementary material.
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been investigated and there are circumstances when 
it may not be of concern.209 214-218 Secondary analyses 
(for example, health economic evaluation) may 
also be afected if appropriate adjustments are not 
made.219 220 Cameron et al221 discuss methodological 
challenges in performing network meta-analysis when 
combining evidence from randomised trials with ADs 
and ixed designs. Statistical methods for estimating 
the treatment efect and its precision exist for some 
ADs68 222-231 and implementation tools are being 
developed.82 232-234 However, these methods are rarely 
used or reported and the implications are unclear.49 209 
235 Debate and research on inference for some ADs with 
complex adaptations is ongoing.
In addition to statistical methods for comparing 
outcomes between groups (item 12a), we specii-
cally encourage authors to clearly describe statistical 
methods used to estimate measures of treatment efects 
with associated uncertainty (for example, conidence 
or credible intervals) and p-value (when appropriate); 
referencing relevant literature is suicient. When 
conventional or naïve estimators derived from ixed 
design methods are used, it should be clearly stated. 
In situations where statistical simulations were used 
to either explore the extent of bias in estimation of 
the treatment efects (such as181 236) or operating 
characteristics, it is good practice to mention this and 
provide supporting evidence (item 24c).
ADs tend to increase the risk of making misleading 
or unjustiied claims of treatments efects if traditional 
methods that ignore trial adaptations are used. 
In general, this arises when selecting one or more 
hypothesis test results from a possible list in order to 
claim evidence of the desired conclusion. For instance, 
the risks may increase by testing the same hypothesis 
several times (for example, at interim and inal 
analyses), hypothesis testing of multiple treatment 
comparisons, selecting an appropriate population from 
multiple target populations, adapting key outcomes, 
or a combination of these.22 A variety of adaptive 
statistical methods exist for controlling speciic 
operating characteristics of the design (for example, 
type I error rate, power) depending on the nature of the 
repeated testing of hypotheses.51 61 62 82 192 237-242
Authors should therefore state operating characteri-
stics of the design that have been controlled and 
details of statistical methods used. The need for 
controlling a speciic type of operating characteristic 
(for example, pairwise or familywise type I error rate) 
is context dependent (for example, based on regulatory 
considerations, objectives and setting) so clariication 
is encouraged to help interpretation. How evidence 
of beneit and/or risk is claimed (part of item 7a) and 
hypotheses being tested (item 2b) should be clear. In 
situations where statistical simulations were used, we 
encourage authors to provide a report, where possible 
(item 24b).
When data or statistical tests across independent 
stages are combined to make statistical inference, 
authors should clearly describe the combination test 
method (for example, Fisher’s combination method, 
inverse normal method or conditional error function)192 
240 241 243 244 and weights used for each stage (when 
not obvious). This information is important because 
diferent methods and weights may produce results 
that lead to diferent conclusions. Bauer and Einfalt107 
found low reporting quality of these methods.
Brard et al245 found evidence of poor reporting of 
Bayesian methods. To address this, when a Bayesian 
AD is used, authors should detail the model used 
for analysis to estimate the posterior probability 
distribution; the prior distribution used and rationale 
for its choice; whether the prior was updated in light 
of interim data and how; and clarify the stages when 
the prior information was used (interim or/and inal 
analysis). If an informative prior was used, the source 
of data to inform this prior should be disclosed where 
applicable. Of note, part of the Bayesian community 
argue that it is not principled to control frequentist 
operating characteristics in Bayesian ADs,246 although 
these can be computed and presented.22 154 247
Typically, ADs require quickly observed adaptation 
outcomes relative to the expected length of the trial. 
In some ADs, randomised participants who have 
received the treatment may not have their outcome 
data available at the interim analysis (referred to as 
overrunning participants) for various reasons.248 
These delayed responses may pose ethical dilemmas 
depending on the adaptive decisions taken, present 
logistical challenges, or diminish the eiciency of the 
AD depending on their prevalence and the objective of 
the adaptations.201 It is therefore useful for readers to 
understand how overrunning participants were dealt 
with at interim analyses especially after a terminal 
adaptation decision (for example, when a trial or 
treatment groups were stopped early for eicacy or 
futility). If outcome data of overrunning participants 
were collected, a description should be given of how 
these data were analysed and combined with interim 
results after the last interim decision was made. Some 
formal statistical methods to deal with accrued data 
from overrunning participants have been proposed.249
See box 17 for exemplars.
Section 13. Results (Participant flow)
Ŷ CONSORT 2010 item 13a: For each group, the 
numbers of participants who were randomly 
assigned, received intended treatment, and were 
analysed for the primary outcome
Box 16: Exemplars on reporting item 12a elements
ɑ([DPSOHʴ )UHTXHQWLVW$'
 ƕ Authors are referred to the CONSORT 2010 statement3  4 for examples.
ɑ([DPSOHʵ ʵ VWDJH%D\HVLDQELRPDUNHUEDVHG$'ZLWK5$5
 ƕ In a methods paper, Gu et al208 detail Bayesian logistic regression models 
for evaluating treatment and marker effects at the end of stage 1 and 2 using 
non-informative normal priors during RAR and futility early stopping decisions. 
Strategies for variable selection and model building at the end of stage 1 to 
identify further important biomarkers for use in RAR of stage 2 patients are 
described (part of item 3b), including a shrinkage prior used for biomarker 
selection with rationale.
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Ŷ ACE item 13a (modiication): For each group, 
the numbers of participants who were randomly 
assigned, received intended treatment, and were 
analysed for the primary outcome and any other 
outcomes used to inform pre-planned adaptations, 
if applicable
Comments—Authors are referred to the CONSORT 
2010 statement3 4 for detailed discussion. Here, we 
only address additional requirements for ADs.
Explanation—The CONSORT 2010 statement3 4 dis-
cusses why it is essential to describe participant low 
adequately from screening to analysis. This applies to 
both interim and inal analyses depending on the stage 
of reporting. The number of participants for each group 
with adaptation outcome data (that contributed to the 
interim analyses) should also be reported if diferent 
from the number of participants with primary outcome 
data. Furthermore, authors should report the number 
of randomised participants, for each group, that did 
not contribute to each interim analysis because of 
lack of mature outcome data at that interim look. For 
example, overrunning participants that were still being 
followed up when a terminal adaptation decision was 
made (for example, dropping of treatment groups or 
early trial termination). The presentation of participant 
low should align with the key hypotheses (for 
example, subpopulation(s) and full study population) 
and treatment comparisons depending on the stage of 
results being reported.
See box 18 for exemplars.
Section 14. Results (Recruitment)
Ŷ CONSORT 2010 item 14a: Dates deining the 
periods of recruitment and follow-up
Ŷ ACE item 14a (modiication): Dates deining the 
periods of recruitment and follow-up, for each 
group
Comment—Authors should refer to the CONSORT 
2010 statement3 4 for the discussion.
Explanation—Consumers of research indings should 
be able to put trial results, study interventions, and 
comparators into context. Some ADs, such as those 
that evaluate multiple treatments allowing dropping 
of futile ones, selection of promising treatments, or 
Box 17: Exemplars on reporting item 12 elements
ɑ([DPSOHʴ *6'VWDWLVWLFDOPHWKRGIRUHVWLPDWLQJWUHDWPHQWHIIHFWV
 ƕ “Stagewise ordering was used to compute the unbiased median estimate and confidence limits for the prognosis-group-adjusted hazard 
rates.250 ”251
ɑ([DPSOHʵ ,QIHUHQWLDOO\VHDPOHVVʷDUPʵ VWDJH$'ZLWKGRVHVHOHFWLRQVWDWLVWLFDOPHWKRGVIRUFRQWUROOLQJRSHUDWLQJFKDUDFWHULVWLFV
 ƕ “…the power of the study ranged from 71% to >91% to detect a treatment difference at a one-sided α of 0.025 when the underlying response rate 
of ≥1 of the crofelemer dose groups exceeded placebo by 20%. The clinical response of 20% was based on an estimated response rate of 55% in 
crofelemer and 35% in placebo during the 4-week placebo-controlled assessment period.… For the primary endpoint, the test for comparing the 
placebo and treatment arms reflected the fact that data were gathered in an adaptive fashion and controlled for the possibility of an increased 
Type I error rate. Using the methods of Posch and Bauer,68 as agreed upon during the special protocol assessment process, a p-value was 
obtained for comparison of each dose to the placebo arm from the stage I data, and an additional p-value was obtained for comparison of the 
optimal dose to the placebo arm from the independent data gathered in stage II. For the final primary analysis, the p-values from the first and 
second stages were combined by the inverse normal weighting combination function, and a closed testing procedure was implemented to test 
the null hypothesis using the methods of Posch and Bauer,68 based on the original work of Bauer and Kieser.69 This closed test controlled the 
experiment-wise error rate for this 2-stage adaptive design at a one-sided α of 0.025.”252 Extracted from appendix material.
ɑ([DPSOHʶ ʶ DUPʵ VWDJHJURXSVHTXHQWLDO$'ZLWKWUHDWPHQWVHOHFWLRQFRPELQDWLRQWHVWPHWKRGPXOWLSOLFLW\DGMXVWPHQWVVWDWLVWLFDOPHWKRGIRU
HVWLPDWLQJWUHDWPHQWHIIHFWV
 ƕ “The proposed closed testing procedure will combine weighted inverse normal combination tests using pre-defined fixed weights, the closed 
testing principle,68 253 254 and the Hochberg-adjusted 1-sided P-value on stage 1 data. This testing procedure strongly controls the overall 
type I error rate at α level (see “Simulations run to assess the type I error rate under several null hypothesis scenarios”). Multiplicity-adjusted 
flexible repeated 95% 2-sided CIs217 on the percentage of patients will be calculated for otamixaban dose 1, otamixaban dose 2, and UFH plus 
eptifibatide. Relative risk and its 95% 2-sided CIs will also be calculated. Point estimates based on the multiplicity-adjusted flexible repeated CIs 
will be used.”181 See supplementary material of the paper for details.
ɑ([DPSOHʷ 3RSXODWLRQHQULFKPHQW$'ZLWK665FULWHULDIRUFODLPLQJHYLGHQFHRIEHQHILWPHWKRGVIRUFRQWUROOLQJIDPLO\ZLVHW\SH,HUURU
FRPELQDWLRQWHVWZHLJKWV
 ƕ Mehta et al99 published a methodological paper detailing a family of three hypotheses being tested; use of closure testing principle254 to 
control the overall type I error; how evidence is claimed; and analytical derivations of the Simes adjusted p-values.255 This includes the use of 
a combination test approach using pre-defined weights based on the accrued information fraction for the full population (cutaneous and non-
cutaneous patients) and subpopulation (cutaneous patients). Analytical derivations were presented for the two cases assuming enrichment 
occurs at interim analysis and no enrichment after interim analysis. Details are reported in a supplementary file accessible via the journal 
website.
ɑ([DPSOHʸ ,QIHUHQWLDOO\VHDPOHVVʺDUPʵ VWDJH$'ZLWKGRVHVHOHFWLRQXVHRIWUDGLWLRQDOQD±YHHVWLPDWHV
 ƕ “Unless otherwise stated, efficacy data are given as least squares means with standard error (SE) or 95% confidence interval (CI).”80
ɑ([DPSOHʹ ,QIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶʸDUPʵ VWDJH$'ZLWKGRVHVHOHFWLRQGHDOLQJZLWKRYHUUXQQLQJSDUWLFLSDQWV
 ƕ “Patients already assigned to an unselected regimen of propranolol by the time that the conclusions of the interim analysis are available, will 
continue the treatment according to the protocol but efficacy data for these patients will not be included in the primary analysis of primary 
endpoint.”98 Extracted from the supplementary material.
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addition of new treatments to an ongoing trial,19 106 258 
259 incorporate pre-planned adaptations to drop or add 
new treatment groups during the course of the trial. As 
a result, dates of recruitment and follow-up may difer 
across treatment groups. In addition, the comparator 
arm may also change with time and concurrent or 
non-concurrent controls may be used. There are 
statistical implications that include how analysis 
populations for particular treatment comparisons are 
deined at diferent stages. For each treatment group, 
authors should clearly state the exact dates deining 
recruitment and follow-up periods. It should be stated 
if all treatment groups were recruited and followed-up 
during the same period.
See box 19 for exemplars.
Ŷ CONSORT 2010/ACE item 14b (clariication): Why 
the trial ended or was stopped
Comment—This item should be applied without 
reference to the CONSORT 2010 statement.3 4
Explanation—Some clinical trials are stopped earlier 
than planned for reasons that will have implications 
for interpretation and generalisability of results. For 
example, poor recruitment is a common challenge.261 
This may limit the inference drawn or complicate 
interpretation of results based on insuicient or 
truncated trial data. Thus, the reporting of reasons for 
stopping a trial early including circumstances leading 
to that decision could help readers to interpret results 
with relevant caveats.
The CONSORT 2010 statement,3 4 however, did not 
distinguish early stopping of a trial due to a pre-planned 
adaptation from an unplanned change. To address this 
and for consistency, we have now reserved this item for 
reporting of reasons why the trial or certain treatment 
arm(s) were stopped outside the scope of pre-planned 
adaptations, including those involved in deliberations 
leading to this decision (for example, sponsor, funder, 
or trial monitoring committee). We also introduced item 
14c to capture aspects of adaptation decisions made in 
light of the accumulating data, such as stopping the 
trial or treatment arm because the decision-making 
criterion to do so has been met.
See box 20 for exemplars.
Ŷ ACE item 14c (new): Specify what trial adaptation 
decisions were made in light of the pre-planned 
decision-making criteria and observed accrued 
data
Explanation—ADs depend on adherence to pre-
planned decision rules to inform adaptations. Thus, 
it is vital for research consumers to be able to assess 
whether the adaptation rules were adhered to as pre-
speciied in the decision-making criteria given the 
observed accrued data at the interim analyses. Failure 
to adhere to pre-planned decision rules may undermine 
the integrity of the results and validity of the design by 
afecting the operating characteristics (see item 7b for 
details on binding and non-binding decision rules).
Unforeseeable events can occur that may lead 
to deviations from some pre-planned adaptation 
decisions rules (for example, the overruling or 
ignoring of certain rules). It is therefore essential to 
adequately describe which pre-planned adaptations 
were enforced, which were pre-planned but were 
not enforced or overruled even though the interim 
analysis decision rules indicated an adaptation should 
be made, and which unplanned changes were made 
other than unplanned early stopping of the trial or 
treatment arm(s) covered by item 14b. Pre-planned 
adaptations that were not implemented are diicult 
to assess because the interim decisions made versus 
the pre-planned intended decisions are often poorly 
reported, and reasons are rarely given.115 The rationale 
for ignoring or overruling pre-planned adaptation 
decisions, or making unplanned decisions that 
afect the adaptations should be clearly stated and 
also who recommended or made such decisions (for 
example, the data monitoring committee or adaptation 
committee). This enables assessment of potential bias 
in the adaptation decision-making process, which is 
crucial for the credibility of the trial.
Authors should indicate the point at which the 
adaptation decisions were made (that is, stage of 
results) and any additional design changes that were 
made as a consequence of adaptation decisions (for 
example, change in allocation ratio).
See box 21 for exemplars.
Section 15. Results (Baseline data)
Ŷ CONSORT 2010 item 15: A table showing baseline 
demographic and clinical characteristics for each 
group
Ŷ ACE Item 15a «15 (clariication, renumbered): A 
table showing baseline demographic and clinical 
characteristics for each group
Comments—We renumbered the item to accommodate 
the new item 15b. This item should be applied with 
reference to the CONSORT 2010 statement,3 4 with 
additional requirements for speciic ADs.
Explanation—The presentation of treatment group 
summaries of key characteristics and demographics 
of randomised participants who contributed to 
Box 18: Exemplars on reporting item 13 (participant flowcharts)
ɑ([DPSOHʴ ,QIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶ$'
 ƕ Appendix D is an illustrative structure that could be used to show the flow of 
participants when reporting the final results from a trial such as ADVENT.252
ɑ([DPSOHʵ 3RSXODWLRQHQULFKPHQW$'
 ƕ Appendices E and F illustrate participant flowcharts that could be used for 
a population-enrichment adaptive trial such as TAPPAS,99 which had key 
hypotheses relating to the cutaneous subpopulation and full population 
(cutaneous and non-cutaneous) depending on whether enrichment was done or 
not.
ɑ([DPSOHʶ %D\HVLDQELRPDUNHUWDUJHWHG$'ZLWK5$5
 ƕ Appendix G is an adapted flow diagram from BATTLE256 showing the number of 
participants that contributed to the analysis by biomarker group (subpopulations) 
during fixed randomisation (burn-in period) followed by RAR.
ɑ([DPSOHʷ 0$06$'
 ƕ Appendix H can be adapted for reporting a MAMS trial such as TAILoR.257
 o
n
 17 June 2020 at BVA. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.m115 on 17 June 2020. Downloaded from 
ReseaRch Methods and RepoRting
the bmj | BMJ 2020;369:m115 | doi: 10.1136/bmj.m115 19
results inluences interpretation and helps readers 
and medical practitioners to make judgements about 
which patients the results are applicable to. For some 
ADs, such as population (or biomarker or patient) 
enrichment,87 146 when the study population is con-
sidered heterogeneous, a trial could be designed to 
evaluate if study treatments are efective in speciic pre-
speciied subpopulations or a wider study population 
(full population). A pre-planned adaptation strategy 
may involve testing the efect of treatments in both 
pre-speciied subpopulations of interest and the wider 
population in order to target patients likely to beneit 
the most. For such ADs, it is essential to provide 
summaries of characteristics of those who were 
randomised and who contributed to the results being 
reported (both interim or inal), by treatment group for 
each subpopulation of interest and the full population 
consistent with hypotheses tested. These summaries 
should be reported without hypothesis testing of 
baseline diferences in participants’ characteristics 
because it is illogical in randomised trials.263-266 The 
CONSORT 2010 statement3 4 presents an example of 
how to summarise baseline characteristics.
In the presence of marked diferences in the num-
bers of randomised participants and those included in 
Box 19: Exemplars on reporting item 14a
ɑ([DPSOHʴ 0$06SODWIRUP$'
 ƕ Figure 2 illustrates the graphical reporting of recruitment and follow-up periods for each treatment group including new arms that were added 
during the STAMPEDE trial. Corresponding comparator groups (controls) for treatment comparisons are indicated.
ɑ([DPSOHʵ 3KDVHʵ %D\HVLDQELRPDUNHUWDUJHWHG$'ZLWK5$5
 ƕ “A total of 341 patients were enrolled in the BATTLE study between November 30, 2006, and October 28, 2009, with equally random 
assignments for the first 97 patients and adaptive randomization for the remaining 158.”256
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Fig 2 | Redrawn from Gilson et al.260 Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://
creativecommons.org/licenses/by/4.0/). No changes to the original igure were made.
Box 20: Exemplars on reporting item 14b
ɑ([DPSOHʴ ʵ VWDJH$'ZLWKRSWLRQVIRUIXWLOLW\DQGHIILFDF\HDUO\VWRSSLQJDQG
LQFUHDVHLQVDPSOHVL]HXQSODQQHGWULDOWHUPLQDWLRQ
 ƕ “The planned interim analysis of the study was done in November 2005 after 
125 patients have been (sic) recruited.… According to the adaptive design of 
the study, we therefore calculated another 163 patients per treatment group to 
be required to answer the primary question. Upon the slow accrual up to that 
timepoint, the study coordinators decided to close the trial at the end of 2005. 
Further analysis was regarded to be exploratory.”193
ɑ([DPSOHʵ 6HTXHQWLDOVWHS$'XQSODQQHGWULDOWHUPLQDWLRQ
 ƕ “…the third interim analysis indicated unexpectedly low initial cure rates in both 
arms; 84% in the multiple dose and 73% in the single-dose arm. The stopping 
rule was not met …, but based on the observed poor efficacy overall, and following 
discussions with the Data Safety and Monitoring Board (DSMB) and investigators, 
the sponsor terminated the trial.”262
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the interim or inal analyses, authors are encouraged 
to report baseline summaries by treatment group 
for these two populations. Readers will then be able 
to assess representativeness of the interim or inal 
analysis population relative to those randomised and 
also the target population.
See box 22 for an exemplar.
Ŷ ACE item 15b (new): Summary of data to enable 
the assessment of similarity in the trial population 
between interim stages
Comment—This item is applicable for ADs conducted 
in distinct stages for which the trial has progressed 
beyond the irst stage.
Explanation—Changes in trial conduct and other 
factors may introduce heterogeneity in the characteri-
stics or standard management of patients before and 
after trial adaptations. Consequently, results may be 
inconsistent or heterogeneous between stages (interim 
parts) of the trial.201 For ADs, access to interim results 
or mere guesses based on interim decisions taken may 
inluence behaviour of those directly involved in the 
conduct of the trial and thus introduce operational 
bias.22 Some trial adaptations may introduce intended 
changes to inclusion or exclusion criteria (for example, 
population enrichment92 146). Unintended changes 
to characteristics of patients over time may occur 
(population drift).267 A concern is whether this could 
lead to a trial with a diferent study population that does 
not address the primary research objectives.268 This 
jeopardises validity, interpretability, and credibility 
of trial results. It may be diicult to determine 
whether diferences in characteristics between stages 
occurred naturally due to chance, were an unintended 
consequence of pre-planned trial adaptations, 
represent operational bias introduced by knowledge 
or communication of interim results, or are for other 
reasons.269 However, details related to item 11c may 
help readers make informed judgements on whether 
any observed marked diferences in characteristics 
between stages are potentially due to systematic bias 
or just chance. Therefore, it is essential to provide key 
summary data of participants included in the analysis 
(as discussed in item 15a) for each interim stage of the 
trial and overall. Authors are also encouraged to give 
summaries by stage and treatment group. This will 
help readers assess similarity in the trial population 
between stages and whether it is consistent across 
treatment groups.
See box 23 for an exemplar.
Section 16. Results (Numbers analysed)
Ŷ CONSORT 2010/ACE item 16 (clariication): For 
each group, number of participants (denominator) 
included in each analysis and whether the analysis 
was by original assigned groups
Comments—The item should be used in reference 
to the CONSORT 2010 statement3 4 for original details 
and examples. Here, we give additional clariication 
for some speciic requirements of certain ADs such as 
population enrichment.87 146
Explanation—We clarify that the number of partici-
pants by treatment group should be reported for each 
analysis at both the interim analyses and inal analysis 
whenever a comparative assessment is performed 
(for example, for eicacy, efectiveness, or safety). 
Most importantly, the presentation should relect the 
key hypotheses considered to address the research 
questions. For example, population (or patient or 
biomarker) enrichment ADs can be reported by 
treatment group for each pre-speciied subpopulation 
and full population depending on key hypotheses 
tested.
Section 17. Results (Outcomes and estimation)
Ŷ CONSORT 2010/ACE item 17a (clariication): For 
each primary and secondary outcome, results for 
each group, and the estimated efect size and its 
precision (such as 95% conidence interval)
Comments—We expanded the explanatory text to 
address some speciic requirements of certain ADs 
such as population enrichment.146 Therefore, the item 
should be used in reference to the CONSORT 20103 for 
original details and examples.
Explanation—In randomised trials, we analyse 
participant outcome data collected after study treat-
ments are administered to address research questions 
about beneicial and/or harmful efects of these 
treatments. In principle, reported results should be in 
line with the pre-speciied estimand(s) and compatible 
with the research questions or objectives.206 207 The 
CONSORT 2010 statement3 4 addresses what authors 
should report depending on the outcome measures. 
These include group summary measures of efect, for 
Box 21: Exemplars on reporting item 14c elements
ɑ([DPSOHʴ %D\HVLDQDGDSWLYHHQULFKPHQW$'ZLWKIXWLOLW\DQGVXSHULRULW\HDUO\
VWRSSLQJVWDJHRIUHVXOWV
 ƕ “Enrolment in the trial was stopped at 31 months, because the results of an 
interim analysis met the pre-specified criterion for trial discontinuation, which 
was a predictive probability of superiority of thrombectomy of at least 95% for 
the first primary endpoint (the mean score for disability on the utility-weighted 
modified Rankin scale at 90 days). This was the first pre-specified interim analysis 
that permitted stopping for this reason, and it was based on the enrolment of 200 
patients. Because enrichment thresholds had not been crossed, the analysis 
included the full population of patients enrolled in the trial, regardless of infarct 
volume.”100
ɑ([DPSOHʵ 'RVHVHOHFWLRQGHFLVLRQVIRUDQLQIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶ$'
 ƕ “The two doses of indacaterol selected against the two reference efficacy criteria 
were 150 µg (as the lowest dose exceeding both criteria) and 300 µg (as the next 
highest dose). The safety results, together with the safety data from the other 
1-year study, led the DMC to conclude that there was no safety signal associated 
with indacaterol at any dose. Thus, the two doses selected (at stage 1) to continue 
into stage 2 of the study were indacaterol 150 and 300 µg.”141
Box 22: Exemplar on reporting item 15a
ɑ([DPSOH3RSXODWLRQHQULFKPHQW$'
 ƕ See Appendix I for a dummy baseline table for the 
TAPPAS trial.99
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both interim and inal analyses, including the number 
of participants contributing to the analysis, appropriate 
measures of the treatment efects (for example, 
between group efects for a parallel group randomised 
trial) and associated uncertainty (such as credible or 
conidence intervals). Importantly, the presentation is 
inluenced by how the key hypotheses are conigured 
to address the research questions. For some ADs, such 
as population (or biomarker or patient) enrichment, 
key hypotheses often relate to whether the study 
treatments are efective in the whole target population 
of interest or in speciic subpopulations of the target 
population classiied by certain characteristics. In such 
ADs, reporting of results as detailed in the CONSORT 
2010 should mirror hypotheses of interest. That is, 
we expect the outcome results to be presented for the 
subpopulations and full target population considered 
by treatment group. This is to help readers interpret 
results on whether the study treatments are beneicial 
to the target population as a whole or only to speciic 
pre-speciied subpopulations.
Ŷ ACE item 17c (new): Report interim results used to 
inform interim decision-making
Explanation—Adherence to pre-planned adaptations 
and decision rules including timing and frequency is 
essential in AD randomised trials. This can only be 
assessed when the pre-planned adaptations (item 3b), 
adaptive decision rules (item 7b), and results that are 
used to guide the trial adaptations are transparently 
and adequately reported.
Marked diferences in treatment efects between 
stages may arise (for example, discussed in item 
15b) making overall interpretation of their results 
diicult.92 110 267 269 270-272 The presence of heteroge-
neity questions the rationale for combining results 
from independent stages to produce overall evidence, 
as is also the case for combining individual studies 
in a meta-analysis.92 273 Although this problem is not 
unique to AD randomised trials, consequences of 
trial adaptation may worsen the problem.269 Authors 
should at least report the relevant interim or stage 
results that were used to make each adaptation, 
consistent with items 3b and 7b; for example, interim 
treatment efects with uncertainty, interim conditional 
power or variability used for SSR, and trend in the 
probabilities of allocating participants to a particular 
treatment group as the trial progresses. Authors 
should report interim results of treatment groups or 
subpopulations that have been dropped due to lack 
of beneit or poor safety. This reduces the reporting 
bias caused by selective disclosure of treatments only 
showing beneicial and/or less harmful efects.
See box 24 for exemplars.
Section 20. Discussion (Limitations)
Ŷ CONSORT 2010/ACE item 20 (clariication): 
Trial limitations, addressing sources of potential 
bias, imprecision, and, if relevant, multiplicity of 
analyses
Comments—No change in wording is made to 
this item so it should be applied with reference to 
the CONSORT 2010 statement3 4 for original details 
and examples. Here, we only address additional 
considerations for ADs.
Explanation—We expect authors to discuss the 
arguments for and against the implemented study 
design and its indings. Several journals have 
guidelines for structuring the discussion to prompt 
authors to discuss key limitations with possible 
explanations. The CONSORT 2010 statement3 4 add-
resses general aspects relating to potential sources 
of bias, imprecision, multiplicity of analyses and 
implications of unplanned changes to methods or 
design. For AD randomised trials, further discussion 
should include the implications of:
Ŷ Any deviations from the pre-planned adaptations 
(for example, decision rules that were not enforced 
or overruled and changes in timing or frequency 
of interim analyses);
Ŷ Interim analyses (for example, updating rando-
misation with inadequate burn-in period);
Ŷ Protocol amendments on the trial adaptations 
and results;
Ŷ Potential sources of bias introduced by interim 
analyses or decision-making;
Ŷ Potential bias and imprecision of the treatment 
efects if naïve estimation methods were used;
Ŷ Potential heterogeneity in patient characteristics 
and treatment efects between stages;
Ŷ Whether outcome data (for example, eicacy and 
safety data) were suicient to robustly inform trial 
adaptations at interim analyses and;
Ŷ Using adaptation outcome(s) diferent from the 
primary outcome(s).
Additionally, it is encouraged to discuss the observed 
eiciencies of pre-planned adaptations in addressing 
the research questions and lessons learned about using 
the AD, both negative and positive. This is optional as 
it does not directly inluence the interpretation of the 
results but enhances much-needed knowledge transfer 
of innovative trial designs. Therefore, authors have 
Box 23: Exemplar on reporting item 15b elements
ɑ([DPSOH2YHUDOOEDVHOLQHFKDUDFWHULVWLFVE\VWDJHLQIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶ
$'. See table 5
Table 5 | Characteristics of randomised participants (N=1202) in stage 1 and 2.
Characteristic Stage 1 (n=230) Stage 2 (n=972)
Age (years), mean (SD) 53.4 (10.3) 54.3 (9.7)
Gender (female), n (%) 139 (60.4) 504 (51.9)
Race (white), n (%) 103 (44.8) 509 (52.4)
BMI (kg/m2), mean (SD) 31.9 (4.5) 31.1 (4.3)
Body weight (kg), mean (SD) 87.3 (18.0) 86.2 (17.1)
Duration of diabetes (years), mean (SD) 7.5 (5.5) 7.0 (5.1)
Seated systolic BP (mm Hg), mean (SD) 128.0 (14.4) 127.7 (13.1)
Seated diastolic BP (mm Hg), mean (SD) 77.9 (7.9) 77.6 (8.6)
Seated heart rate (bpm), mean (SD) 74.5 (9.6) 75.2 (10.0)
Adapted from Geiger et al166; BMI = Body Mass Index; SD = standard deviation; BP = blood pressure; 
bpm = beats per minute; mm Hg = millimetres of mercury. Data presented were from an ongoing trial so are 
incomplete and only used for illustration.
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Box 24: Exemplars on reporting item 17 elements
ɑ([DPSOHʴ %D\HVLDQ5$5;FKDQJHLQUDQGRPLVDWLRQSUREDELOLWLHVDFURVVDUPVWKURXJKRXWWKHWULDOUDQGRPLVDWLRQXSGDWHVZHUHPDGHDIWHUHYHU\
patient
 ƕ Giles et al71 present a table of changes in allocation probabilities used to create figure 3 by treatment group including allocated treatment and 
primary outcome response for each participant.
ɑ([DPSOHʵ ,QIHUHQWLDOO\VHDPOHVVSKDVHʵ ʶ$'VWDJHʴ WUHDWPHQWVHOHFWLRQUHVXOWV
 ƕ Barnes et al141 clearly presented the results that led to the interim selection of the two indacaterol drug doses to progress to stage 2 of the 
study; 150 µg (the lowest dose that exceeded both pre-specified treatment selection criteria) and 300 µg (the next highest dose that met the 
same criteria). The interim difference in treatment effect compared to placebo with uncertainty per group for the two adaptation outcomes are 
displayed in figures 1 and 2 of the paper.
ɑ([DPSOHʶ ʵ VWDJH*6'VWDJHʴ GRVHVHOHFWLRQUHVXOWV
 ƕ “At the interim analysis planned after at least 1969 patients had been randomized and reached day 7 follow-up in each group,181 the otamixaban 
dose for stage 2 of the trial was selected as described in eFigure 1 in the Supplement. At that time, the rates of the primary efficacy outcome in 
the higher-dose otamixaban group was xx (4.7%) (the one selected to go forward) and was xx (5.6%) in the UFH-pluseptifibatide group (adjusted 
RR, 0.848; 95% CI, 0.662-1.087) but the lower-dose group fulfilled the pre-specified criteria for futility with a RR of more than 1 (primary efficacy 
outcome, xx (6.3%); RR, 1.130; 95% CI, 0.906-1.408) and was discontinued.”144 xx are the corresponding number of participants with primary 
response that should have been stated.
ɑ([DPSOHʷ $GDSWHGIURP.KDOLOHWDO143VHTXHQWLDOVWHS$'. See table 6.
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Fig 3 | Redrawn from Pallmann et al.22 Reused in accordance with the terms of Creative Commons Attribution 4.0 International License (https://
creativecommons.org/licenses/by/4.0/). No changes to the original igure were made.
Table 6 | Interim results
Parasite clearance at day 30 (initial cure) Treatment group Parasite clearance rate, n/N (%) Diferences in parasite clearance rates (95% CI) P-value
Interim analysis 1 Single dose, 7.5mg/kg 10/20 (50.0%) Reference
Multiple dose, 7x3mg/kg 16/18 (88.9%) 38.9% (12.6 to 65.2) 0.015a
Interim analysis 2b Single dose, 10mg/kg 16/20 (80.0%) Reference
Multiple dose, 7x3mg/kg 19/25 (76.0%) −4.0% (−28.2 to 20.2) 0.748c
Interim analysis 3d Single dose, 10mg/kg 29/40 (72.5%) Reference
Multiple dose, 7x3mg/kg 37/44 (84.1%) 11.6% (−6.0 to 29.1) 0.196e
N, total number of patients per group (denominator); n, patients with recorded parasitic clearance per groups (events); CI, conidence interval; a p-value from Fisher’s exact test, adaptation 
rule met to escalate dose so dosage increased to 10 mg/kg and continue recruitment; b adaptation rule to escalate dose not met so recruitment was continued with the same dosage (10mg/
kg in single-dose arm; c, e p-values from a Chi-square test; e adaptation rule to escalate dose not met but concerns arose regarding low cure in each arm and recruitment was terminated; d 
includes patients in interim analysis 2; patients in interim analysis 1 did not contribute to any subsequent interim analysis.
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been encouraged to consider separate methodology 
publications in addition to trial results.58 181
See box 25 for exemplars.
Section 21. Discussion (Generalisability)
Ŷ CONSORT 2010/ACE item 21 (clariication): 
Generalisability (external validity, applicability) of 
the trial indings
Comments—We have not changed the wording of 
this item so it should be considered in conjunction 
with the CONSORT 2010 statement.3 4 However, there 
are additional considerations that may inluence the 
generalisability of results from AD randomised trials.
Explanation—Regardless of the trial design, authors 
should discuss how the results are generalisable to 
other settings or situations (external validity) and 
how the design and conduct of the trial minimised or 
mitigated potential sources of bias (internal validity).3 
For ADs, there are many factors that may undermine 
both internal (see item 20 clariications) and external 
validity. Trial adaptations are planned with a clear 
rationale to achieve research goals or objectives. Thus, 
the applicability of the results may be intentionally 
relevant to the target population enrolled or pre-
speciied subpopulation(s) with certain characteristics 
(subsets of the target population). Speciically, the 
implemented adaptations and other factors may 
cause unintended population drift or inconsistencies 
in the conduct of the trial. Authors should discuss 
the population to whom the results are applicable 
including any threats to internal and external validity 
which are trial dependent based on the implemented 
adaptations.
See box 26 for exemplars.
Section 24. Other information (Statistical analysis 
plan and other relevant trial documents)
Ŷ ACE item 24b (new): Where the full statistical 
analysis plan and other relevant trial documents 
can be accessed
Explanation—Pre-specifying details of statistical 
methods and their execution including documentation 
of amendments and when they occurred is good 
scientiic practice that enhances trial credibility and 
reproducibility of methods, results and inference. The 
SAP is the principal technical document that details 
the statistical methods for the design of the study; 
analysis of the outcomes; aspects that inluence the 
analysis approaches; and presentation of results 
consistent with the research questions/objectives and 
estimands206 207 in line with the trial protocol (now 
item 24a). General guidance on statistical principles 
Box 25: Exemplars on reporting item 20
ɑ([DPSOHʴ 8VHRIVXUURJDWHRXWFRPHWRLQIRUPDGDSWDWLRQ
 ƕ “We chose change in the SOFA scores as a surrogate outcome based on strong correlations between this measure and 28-day mortality (33). 
Whether change in the SOFA scores and the timing of reassessment (48 hours in this case) represents the “right” surrogate endpoint for 
nonpivotal sepsis trials remains unclear and is an area for future consideration, although the use of change in the SOFA score as a surrogate 
outcome is supported by a recent meta-analysis (34).”142
ɑ([DPSOHʵ 'XUDWLRQRIDVVHVVPHQWVWRLQIRUPGRVHVHOHFWLRQ
 ƕ “The use of the adaptive seamless design is not without potential risk. The initial dose-finding period needs to be long enough for a thorough 
evaluation of effects. Two weeks was considered a fully adequate period in which to attain pharmacodynamic steady state….”141
ɑ([DPSOHʶ (DUO\VWRSSLQJRXWVLGHWKHVFRSHRIWKHSUHSODQQHGDGDSWDWLRQDQGSRVVLEOHH[SODQDWLRQ
 ƕ “The aim was to determine the minimum efficacious dose and safety of treatments in HIV-uninfected patients. However, the study had to be 
prematurely terminated due to unacceptably low efficacy in both the single and multiple dose treatment arms, with a cure rate of only 85% in the 
multiple-dose arm. Adverse effects of treatment in this study were in line with the current drug label. The overall low efficacy was unexpected, 
as total doses of 10 mg/kg and above resulted in DC rates of at least 90% in a trial in Kenya (13). The trial was not powered for data analysis 
by geographical location (centre) and the results may have been due to chance, but both the 10 mg/kg single dose and 21 mg/kg multiple 
dose regimens appeared to work very well in the small number of patients treated in Arba Minch Hospital (southern Ethiopia). We have little 
explanation for the overall poor response seen in this study or for the observed geographical variations. Previously, similar geographical 
variation in treatment response in these three sites was seen for daily doses of 11 mg/kg body weight paromomycin base over 21 days (7), a 
regimen which had also proven efficacious in India (18). Methodological bias is unlikely in this randomized trial, but differences in base line 
patient characteristics between the three trial sites could have possibly introduced bias, leading to variation in treatment response….”143
ɑ([DPSOHʷ /LPLWDWLRQVRIELRPDUNHUVDQG5$5
 ƕ “Our study has some important limitations. First, and probably most important, our biomarker groups were less predictive than were individual 
biomarkers, which diluted the impact of strong predictors in determining treatment probabilities. For example, EGFR mutations were far more 
predictive than was the overall EGFR marker group. The unfortunate decision to group the EGFR markers also impacted the other marker groups 
and their interactions with other treatments, resulting in a suboptimal overall disease control rate as described. Second, several of the pre-
specified markers (for example, RXR) had little, if any, predictive value in optimizing treatment selections. This limitation will be addressed in 
future studies by not grouping or prespecifying biomarkers prior to initiating these biopsy-mandated trials. In addition, adaptive randomization, 
which assigns more patients to the more effective treatments within each biomarker group, only works well with a large differential efficacy 
among the treatments (as evident in the KRAS/BRAF group), but its role is limited without such a difference (for example, in the other marker 
groups). Allowing prior use of erlotinib was another limitation and biased treatment assignments; in fact, the percentage of patients previously 
treated with erlotinib steadily increased during trial enrollment. Overall, 45% of our patients were excluded from the 2 erlotinib-containing arms 
because of prior EGFR TKI treatment. As erlotinib is a standard of care therapy in NSCLC second-line, maintenance, and front-line settings, the 
number of patients receiving this targeted agent will likely continue to increase.”256
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for clinical trials to consider with the aim to standardise 
research practice exists.274-276 AD trials tend to bring 
additional statistical complexities and considerations 
during the design and analyses depending on the 
trial adaptations considered. Access to the full SAP 
with amendments (if applicable) addressing interim 
and inal analyses is essential. This can be achieved 
through the use of several platforms such as online 
supplementary material, online repositories, or 
referencing published material. This enables readers to 
access additional information relating to the statistical 
methods that may not be feasible to include in the 
main report.
Critical details of the trial adaptations (for example, 
the decision-making criteria or adaptation algorithm 
and rules) may be intentionally withheld from publicly 
accessible documents (for example, protocol) while the 
trial is ongoing.45 203 These details may be documented 
in a formal document with restricted access and 
disclosed only when the trial is completed in order to 
minimise operational bias (item 11c). For this situation, 
authors should provide access to such details withheld 
with any amendments made for transparency and an 
audit trail of pre-planned AD aspects.
For some AD randomised trials, methods to derive 
statistical properties analytically may not be available. 
Thus, it becomes necessary to perform simulations 
under a wide range of plausible scenarios to inves-
tigate the operating characteristics of the design 
(item 7a), impact on estimation bias (item 12b), and 
appropriateness and consequences of decision-making 
criteria and rules.154 277 In such cases, we encourage 
authors to reference accessible material used for this 
purpose (for example, simulation protocol and report, 
or published related material). Furthermore, it is good 
scientiic practice to reference software, programs 
or code used for this task to facilitate reproducible 
research.
The operating characteristics of ADs heavily depend 
on following the pre-planned adaptations and adaptive 
decision-making criteria and rules. ADs often come 
with additional responsibilities for the traditional 
monitoring committees or require a specialised moni-
toring committee to provide independent oversight of 
the trial adaptations (for example, adaptive decision-
making or adaptation committee). Thus, it is essential 
to be transparent about the adaptation decision-making 
process, roles and responsibilities of the delegated 
DMC(s), recommendations made by the committee and 
whether recommendations were adhered to. Authors 
are encouraged to provide supporting evidence (for 
example, DMC charter).
See box 27 for exemplars.
Conclusions
There is a multidisciplinary desire to improve eiciency 
in the conduct of randomised trials. ADs allow pre-
planned adaptations that ofer opportunities to 
address research questions in randomised trials more 
eiciently compared to ixed designs. However, ADs 
can make the design, conduct and analysis of trials 
more complex. Potential biases can be introduced 
during the trial in several ways. Consequently, there are 
additional demands for transparency and reporting to 
enhance the credibility and interpretability of results 
from adaptive trials.
This CONSORT extension provides minimum essen-
tial reporting requirements that are applicable to pre-
planned adaptations in AD randomised trials, designed 
and analysed using frequentist or Bayesian statistical 
methods. We have also given many exemplars of 
diferent types of ADs to help authors when using 
Box 26: Exemplar on reporting item 21 elements
ɑ([DPSOHʴ %D\HVLDQSRSXODWLRQHQULFKPHQW$'ZLWK5$5WRZKRPWKHUHVXOWVDUH
DSSOLFDEOHIXOOSRSXODWLRQ
 ƕ “The DAWN trial showed that, among patients with stroke due to occlusion of the 
intracranial internal carotid artery or proximal middle cerebral artery who had last 
been known to be well 6 to 24 hours earlier and who had a mismatch between 
the severity of the clinical deficit and the infarct volume, outcomes for disability 
and functional independence at 90 days were better with thrombectomy plus 
standard medical care than with standard medical care alone.”100
ɑ([DPSOHʵ 3KDVHʵ %D\HVLDQELRPDUNHUWDUJHWHG$'ZLWK5$5WRZKRPWKHUHVXOWV
DUHDSSOLFDEOHELRPDUNHUVSHFLILF
 ƕ “Sorafenib was active against tumors with mutated or wild-type KRAS, but had a 
worse disease control rate (compared with other study agents) in patients with 
EGFR mutations. As expected (5–7, 15–17), erlotinib was beneficial in patients 
with mutated-EGFR tumors. Erlotinib plus bexarotene improved disease control 
in patients with a higher expression of Cyclin D1, suggesting a potential role for 
bexarotene in lung cancer treatment (11); similar to sorafenib, the combination 
also improved disease control in the KRAS-mutant patient population. Future 
randomized, controlled studies are needed to further confirm the predictive 
value of these biomarkers.”256 Liu and Lee85 published details of the design and 
conduct of this trial.
Box 27: Exemplars on reporting item 24b
ɑ([DPSOHʴ ,QWHULPDQGILQDO6$3V,'0&UROHVDQGUHVSRQVLELOLWLHVVXSSOHPHQWDU\
PDWHULDO
 ƕ Léauté-Labrèze et al98 provide several versions of the SAP for a 2-stage inferentially 
seamless phase 2/3 AD as supplementary material. The remit and responsibilities 
of the IDMC including involvement in the adaptation decision-making process are 
detailed. The last version (3.5) of the SAP with amendments and details of interim 
and final analyses is found on pages 759 to 830 of the protocol supplementary 
material. Simulation results are summarised on pages 831 to 836.
ɑ([DPSOHʵ 6LPXODWLRQUHSRUWVXSSOHPHQWDU\PDWHULDO
 ƕ Steg et al181 provide a simulation report evaluating the operating characteristics 
of a 3-arm 2-stage group sequential AD with dose selection under a number of 
scenarios in an appendix. The authors also explored the bias in methods used to 
estimate the treatment effects and confidence intervals and used the simulation 
results to inform their choice of methods.
ɑ([DPSOHʶ 6HWXSRIVLPXODWLRQVWXGLHVDQGVLPXODWLRQUHVXOWVSXEOLVKHG
PHWKRGRORJ\ZRUN
 ƕ Gu et al208 describe how simulation studies were performed and presented 
simulation results for evaluating operating characteristics of a 2-stage Bayesian 
biomarker-based AD.
ɑ([DPSOHʷ 6LPXODWLRQUHSRUWSXEOLVKHGPHWKRGRORJ\ZRUN
 ƕ Skrivanek et al154 published extensive simulation work quantifying operating 
characteristics of a Bayesian inferentially seamless phase 2/3 AD with RAR.
ɑ([DPSOHʸ 6LPXODWLRQUHSRUWSXEOLVKHGPHWKRGRORJ\ZRUN
 ƕ Heritier et al67 published extensive simulation work for an inferentially seamless 
phase 2/3 design using frequentist methods.
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this extension. Our consensus process involved 
stakeholders from the public and private sectors.13 128 
We hope this extension will facilitate better reporting 
of randomised ADs and indirectly improve their design 
and conduct, as well as much-needed knowledge 
transfer.
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Appendix A: Main ACE checklist available to download
Appendix B: Additional examples of Box 13
Appendix C: Example 2 of Box 14 (Bayesian RAR)
Appendix D: Example of a CONSORT lowchart for 
reporting 2-stage adaptive design (such as inferential 
seamless) that use combination test methods
Appendix E: Example of a CONSORT lowchart for 
reporting a population enrichment adaptive design 
(assuming enrichment was done at an interim analysis)
Appendix F: Example of a CONSORT lowchart for 
reporting a population enrichment adaptive design 
(assuming enrichment was not done at an interim 
analysis)
Appendix G: Example of a CONSORT lowchart for 
reporting a response-adaptive randomisation design 
with frequent randomisation updates
Appendix H: Example of a CONSORT lowchart for 
reporting a MAMS adaptive design
Appendix I: Box 22 - Dummy baseline table for the 
TAPPS trial
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